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ABSTRACT 
 
Staphylococcus pseudintermedius is a coagulase positive bacterium and found on the mucous 
membranes of approximately 90% of healthy dogs. This organism is an opportunistic pathogen 
in dogs and an increasingly recognized zoonoses. As in human medicine, the emergence of 
antimicrobial resistance is a growing problem in companion animal practice. In the current 
investigation, we saught to 1. Identify the emergence of resistance among S. pseudintermedius 
colonizing healthy dogs, 2. Determine whether there are strain specific tissue tropisms among 
isolates causing dermatological and urinary tract infections, 3. Perform a clinical and 
bacteriological description of human S. pseudintermedius infections and 4. To describe the 
correlation of susceptibility of isolates to tetracycline, doxycycline and minocycline, and to 
describe the mechanisms of tetracycline resistance. We found that methicillin-resistant S. 
pseudintermedius colonizes 7% of healthy dogs and that since a previous surveillance study 
conducted in 2008, resistance has emerged in our region. S. pseudintermedius isolates from 
dermatological and urinary tract infections were genetically heterogeneous, suggesting that these 
organisms are true opportunists and do not possess a strain specific tissue tropism. Despite this 
genetic heterogeneity, antimicrobial resistance was found to be significantly higher in isolates 
from dermatological infections compared to those from the urinary tract. Human infections with 
S. pseudintermedius were relatively rare, comprising 0.05% of skin and soft tissue infections in a 
large Canadian health region. Among these human isolates, we found that all methicillin resistant 
isolates were the European pandemic clones ST71 and ST181. We found that tetracycline is not a 
satisfactory indicator for doxycycline and minocycline resistance, and that these phenotypic 
discrepancies could not be explained by the presence or absence of particular resistance genes. 
Furthermore, factors related to tetM (which was the most commonly identified resistance gene) 
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including copy number, predicted amino acid sequence or expression level, were not 
significantly associated with the phenotypic diversity observed. Although numerically high 
association were found in high MIC category on tetM expression comparing to low MIC 
category, larger studies required for further conclusions. The genotypic evidence on MICs for 
tetracycline and doxycycline is largely unknown and more studies are required. 
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1 INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Taxonomy, basics biochemical characteristics and identification of 
Staphylococcus pseudintermedius 
Staphylococcus pseudintermedius is a Gram-positive cocci normally found as a part of the skin-
associated bacterial populations of dogs (Bannoehr and Guardabassi, 2012; Rubin and Chirino-
Trejo, 2011). S. pseudintermedius grows as grayish colonies 1-2 mm on 5% sheep blood agar 
and is typically associated with a double zone of hemolysis (Markey et al., 2013). Based on 
DNA-DNA hybridization and the recognized natural host specificity, S. pseudintermedius was 
described as a separate species in 2007 (Sasaki et al., 2007b). Staphylococcus pseudintermedius, 
Staphylococcus intermedius, and Staphylococcus delphini are collectively called the S. 
intermedius group (Bannoehr and Guardabassi, 2012). These species cannot be reliably 
distinguished from each other using phenotypic tests or commercial diagnostic kits (Bannoehr 
and Guardabassi, 2012). The morphological and biochemical characteristics of Staphylococci 
found in dogs have been summarized in Table 1.1.  
The morphological similarity between S. pseudintermedius and S. aureus results in these 
organisms being misdiagnosed at human diagnostic laboratories, although they can be 
distinguished by a number of biochemical tests including hyaluronidase and acetoin production, 
polymyxin B susceptibility and carbohydrate fermentation tests such as maltose, trehalose, 
mannitol, galactose, lactose (Table 1.1) (Bannoehr and Guardabassi, 2012; Borjesson et al., 
2015). Moreover, S. pseudintermedius is only positive using the tube coagulase and may be 
misidentified as being coagulase negative due to the poor response in the slide coagulase test and 
commercial latex agglutination test (Bannoehr and Guardabassi, 2012). More recently, molecular 
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methods including PCR amplification of species-specific target, sequencing of PCR products, 
and Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MOLDI-
TOF MS) are being used for the identification of S. pseudintermedius. 
Multiplex PCR assays have been developed based on the amplification of the thermoneuclease 
(nuc) gene which differentiates S. pseudintermedius from S. aureus, S. hyicius, S. schleiferi, S. 
intermedius, S. pseudintermedius, and S. delphini (Sasaki et al., 2010). The phylogenetic analysis 
of the nuc, kat, soda, and gap genes has also been used to identify different species of 
Staphylococcus (Blaiotta et al., 2010). Currently, the universal bacterial target cpn60 and 16S 
rRNA are widely used for speciation due to the slow rate of evolution of this gene (Hill et al., 
2004; Wakita et al., 2002). However, MALDI-TOF MS is emerging in a trend which has 
replaced many of conventional bacteriological tests in current diagnostic laboratories 
(Murugaiyan et al., 2014; Silva et al., 2015). In MALDI-TOF MS, microbial proteins are ionized 
into charged molecules and the mass to charge ratio is measured by time of flight mass 
spectrometry (Singhal et al., 2015). The identification of a species is based on the ratio of mass 
and charge which is unique to each species of bacteria (Biswas and Rolain, 2013). In this 
method, isolated bacterial colonies are simply overlaid with matrix and are exposed to a fixed 
pulsed laser beam.  
 
 
 
3
 
Table 1.1: Morphological and biochemical characteristics of coagulase positive Staphylococci species found in dogs. 
Test S. aureus S. pseudintermedius S. intermedius S. delphini S. schleiferi 
Hemolysis + + + + + 
Tube coagulase + + + + + 
Slide coagulase + +/- + + + 
Acetoin production + variable - - + 
DNAse + + + weak + + 
Trehalose + + + - - 
Maltose + + + + - 
Mannitol + - - + variable 
Hyaluronidase + - - - - 
Pyrrolidinyl acryl amidase - - - not known + 
Beta galactosidase - + + + variable 
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1.1.1 Epidemiology of Staphylococcus pseudintermedius 
1.1.1.1 Geographical distribution of the organism reported 
Staphylococcus pseudintermedius has been reported in many locations around the world, 
although there may be publication bias towards North America and Europe, where funding 
opportunities, technical skills, and advanced laboratory facilities are more readily available.4 In 
addition, many studies originate in Japan, South Korea, and Thailand, with more recent studies 
emerging from Australia and New Zealand (Saputra et al., 2017). Few studies from Africa and 
South America have been published. As of June 9, 2017, there were 391 papers describing S. 
pseudintermedius in PubMed (S. intermedius was not included). Nearly 300 of these papers 
highlighted the significance of S. pseudintermedius in domestic dogs.  
Staphylococcus pseudintermedius colonizes 90% of healthy dogs (Rubin and Chirino-Trejo, 
2011). The organism is most commonly found in pharynx and rectum but also been isolated from 
the perineum, inguinal region, nares, conjunctiva and skin (Bannoehr and Guardabassi, 2012; 
Iverson et al., 2015). As S. pseudintermedius is isolated from the pharynx, it is also frequently 
found in oral cavity and saliva (Iverson et al., 2015). S. pseudintermedius has also been found in 
mammary secretions perhaps explaining how pups are colonized early in life (Rota et al., 2011). 
The ability to recover the bacterium from a dog depends on multiple factors including whether 
single or multiple anatomical sites are sampled, and which specific sites are included. The rate of 
recovery of S. pseudintermedius was reported to be high from the pharynx (81.1% of colonized 
dogs) compared to the frequency of recovering this organism from the nares (47.7%) (Rubin and 
Chirino-Trejo, 2011). In one study which included only nasal swabs, Staphylococci were only 
recovered from only 37% of dogs (Han et al., 2016). As such, including multiple sampling sites 
improves recovery of the organism, with pharynx and rectum being the preferred sites for the 
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isolation of S. pseudintermedius in dogs (Rubin and Chirino-Trejo, 2011). Dogs can be described 
as either persistent, intermittent or transient carrier of S. pseudintermedius (Gomez-Sanz et al., 
2013a). Persistent carriage describes a situation when S. pseudintermedius is carried for long 
period of time, while transient carriers occasionally harbour the organism. 
Staphylococcus pseudintermedius is less common in cats, with colonization rates varying from 
4.3 - 65% (Abraham et al., 2007; Hanselman et al., 2009). S. pseudintermedius has also been 
reported in a variety of other species such as horses, goats, wild carnivores, feral cats, cows, 
minks, rats, pigeons and human (Bannoehr and Guardabassi, 2012; Iverson et al., 2015; Weese, 
2010). S. pseudintermedius is not a part of the human resident microbiota, it is therefore 
suggested that people acquire this organism through canine contact such as licking or handling of 
pets although the transmission of this organism has not been adequately studied (Gharsa et al., 
2013; Walther et al., 2012).  
 
1.1.1.2 Zoonosis/Interspecies transmission 
Staphylococcus aureus colonizes 30% of the human population and causes a wide variety of 
opportunistic infections (Missiakas and Schneewind, 2016). In contrast, S. pseudintermedius is 
less commonly associated with disease in humans (Deurenberg and Stobberingh, 2008; Hill and 
Imai, 2016). Although the incidence of S. pseudintermedius is unknown, a number of case 
reports including skin and soft tissue infections, sinonasal infection, bone implant and surgical 
site infections have been reported (Borjesson et al., 2015; Kuan et al., 2016; Pompilio et al., 
2015; Savini et al., 2013; Viau et al., 2015). People who suffer from concurrent 
immunosuppressive conditions are more susceptible to the secondary infections and may be 
overrepresented among human patients with S. pseudintermedius infections (Kuan et al., 2016).  
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Among patients with S. pseudintermedius infections, close association with dogs is commonly 
reported suggesting zoonotic transmission (Gomez-Sanz et al., 2013b). Many studies have used 
molecular epidemiological tools to demonstrate common strains within a household providing 
evidence in support of transmission from dog to human (Laarhoven et al., 2011; Lozano et al., 
2017; Walther et al., 2012). Because dogs are frequently pharyngeally colonized, contaminated 
saliva provides ample opportunity for S. pseudintermedius to infect tissues damaged following 
dog bite wounds (Borjesson et al., 2015). Although human infections with S. pseudintermedius 
are a recognized public health risk associated with the canine contact, the magnitude of this risk 
has not been quantified.  
 
1.2 Clinical infection in dogs 
1.2.1 Summary of clinical significance 
The clinical impact of S. pseudintermedius in canine practice cannot be overstated, it is very 
commonly encountered as a cause of infection (Saputra et al., 2017). S. pseudintermedius is an 
opportunistic pathogen, commonly isolated with wounds, abscesses, eye infections and mastitis 
(Bannoehr and Guardabassi, 2012). Importantly, it is the most common cause of dermatological 
infections, otitis externa and the second most common cause of urinary tract infections in dogs 
(Bannoehr and Guardabassi, 2012; Dziva et al., 2015; Windahl et al., 2014). In dogs which 
acquire infections following hospitalization or surgery, a nosocomial origin of the infection has 
frequently been suggested (Bergstrom et al., 2012; Gronthal et al., 2014; Haenni et al., 2013; 
Haenni et al., 2014; Walther et al., 2016; Windahl et al., 2015). Infection control strategies are 
practiced in veterinary clinics to minimize transmission of S. pseudintermedius among animals. 
Transmission to vulnerable patients in hospital settings readily occurs due to temporary 
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suppression of normal host defenses including following surgical disruption of tissues, anesthesia 
and stress associated with hospitalization (Bergstrom et al., 2012; Nazarali et al., 2014). A 
positive association between S. pseudintermedius infection and number of days in intensive care 
or surgery wards, longer overall duration of hospitalization, the severity of concurrent infection 
and long-term usage of antimicrobials have been identified (Gronthal et al., 2014; Singh et al., 
2013; Windahl et al., 2015). Methicillin resistant isolates have been isolated from surgical 
devices at veterinary hospitals, highlighting the possible risk of infection associated with the use 
of nonsterile or improperly sterilized devices (Ishihara et al., 2010). In fact, S. pseudintermedius 
has been isolated from infections of implants following orthopedic surgery in dogs 
(Miedzobrodzki et al., 2010). Staphylococcus pseudintermedius is a biofilm forming bacterium 
even in wound associated infections (Han et al., 2015; Pompilio et al., 2015). The icaA gene 
which causes biofilm has been studied in S. pseudintermedius (Han et al., 2015). In biofilm 
environments, it has been reported to be highly-antimicrobial tolerant towards amoxicillin, 
cephalexin, clindamycin, doxycycline, marbofloxacin and combination antimicrobial protocols 
(Ferran et al., 2016). One study reported that only rifampicin was effective against S. 
pseudintermedius in biofilms while other antimicrobials including chloramphenicol, gentamicin, 
cefoxitin, linezolid, vancomycin, tetracycline, and tigecycline were ineffective in this 
environment (Pompilio et al., 2015).  
 
1.2.2 Pathogenesis and virulence mechanism 
Although the pathogenesis of S. aureus has been investigated in human and livestock, the 
pathogenesis of S. pseudintermedius in companion animals is understudied, with only a few 
virulence factors identified (Fitzgerald, 2009). Putative virulence factors found in S. aureus have 
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been assumed to be present in S. pseudintermedius although their role in disease has not been 
demonstrated (Fitzgerald, 2009). According to clinical experts the pathogenesis of S. 
pseudintermedius depends more upon host factors than on factors associated with the bacterium; 
however, there is insufficient peer-reviewed data to draw conclusions on the magnitude and role 
of these factors (Green, 2012). Although a number of studies have reported lists of virulence 
factors from S. pseudintermedius, the nomenclature used to describe these genes is inconsistent 
and many studies simply publish PCR results without depositing the sequences of DNA 
amplicons in databases such as GenBank. 
Tissue injury, immunosuppression, and concurrent diseases are purported instigating factors of S. 
pseudintermedius infections in dogs (Bannoehr and Guardabassi, 2012). A number of putative 
virulence factors have been described Hill et al, 2016 have summarized virulence factors, host 
immune response and immunopathogenesis in S. pseudintermedius by extrapolating data from S. 
aureus (Hill and Imai, 2016). These factors are involved at multiple stages in the pathogenesis of 
infection from adhesion to immune evasion to spread the infection. Virulence proteins such as 
fibrinogen binding protein, fibronectin binding protein, iron-regulated surface determinants 
facilitate bacterial adhesion to the natural host (corneocyte) and also involved in activation of 
complement pathway and opsonization of the pathogen. Immunoglobins and cell-mediated 
immune responses are inactivated by virulence proteins including superantigen and leucocidin. 
The leucocidin toxin secreted by S. aureus inactivates mononuclear cells and neutrophils (Hill 
and Imai, 2016). Exfoliative toxin (Exi) digest the Dsg 1 protein in the canine skin causing 
acantholysis in canine skin (Iyori et al., 2011). Putative virulence proteins of S. pseudintermedius 
which have been previously published are summarized Table 1.2. 
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While uropathogenic E. coli possess specific nutrient uptake mechanisms (i.e. siderophores) and 
virulence factors such as virulence-associated adhesive surface fibers to survive in the hostile 
environment of the urinary tract in humans and companion animals, similar adaptations have not 
been described in S. pseudintermedius.(Chahales and Thanassi, 2015; Piras et al., 2015).  
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Table 1.2: Virulence factors found in Staphylococcus pseudintermedius 
Virulence factor Function in pathogenesis Reference 
Exi Breaking down epidermis (Iyori et al., 2011) 
Enterotoxin Toxic shock syndrome (Tanabe et al., 2013) 
SpsD, SpsO Corneocyte adhesion (Bannoehr et al., 2012) 
SpsD, SpsL fibronectin binding protein Adhesion to corneum, skin, 
and invasion 
(Pietrocola et al., 2015) 
BacSp222 Cationic peptide Cytotoxic activity on 
eukaryotic cells 
(Wladyka et al., 2015) 
LukS/F-1, ExpA, Se-int, Seccanine, Siet, 
Sea, Seb, Sec, Sed, Sei, Sej, Sek, Ser, 
Hlg 
Invasion and peeling of skin (Gharsa et al., 2013) 
Proteases, clumping factor, protein A Invasion, peeling of skin, 
inactivation of 
immunoglobulin 
(Futagawa-Saito et al., 
2006) 
Seccanine Toxic shock syndrome (Edwards et al., 1997) 
Synergohymentropic Making pores in cells (Prevost et al., 1995) 
SpsA, SpsB, SpsD, SpsK, SpsL, SpsN, 
NucC, Coa, and Luk-I 
Invasion peeling of skin, 
inactivation of 
immunoglobulin 
(Couto et al., 2016a) 
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1.2.3 Dermatological infections 
Staphylococcus pseudintermedius is the most frequent organism identified in canine skin 
infections, being isolated from 80% of clinical submissions (Sindha et al., 2015). Skin infections 
are also referred to as pyoderma and are typically secondary to injury or concurrent disease 
(Beco et al., 2013a). Pyoderma can be identified using a number of tests including physical 
examination, skin scraping, cytological examination, skin biopsy and bacterial culture (Green, 
2012). Canine pyoderma is categorized as surface, superficial and deep pyoderma based on the 
extent of infection in the skin (Beco et al., 2013a). Both surface and superficial pyoderma are 
limited to the epidermis and while deep pyoderma extends to the dermis (Beco et al., 2013a). 
Clinical signs depend upon the severity and site/distribution of the infection (Beco et al., 2013a). 
The pathological and histological findings associated with pyoderma depend upon the severity of 
infections. In patients with superficial pyoderma, a high number of bacterial and inflammatory 
cells are typically found in the stratum corneum and epidermis (Baumer et al., 2017; Beco et al., 
2013a). In deep pyoderma, the bacteria spread into the dermis resulting in deeper inflammation 
and furunculosis followed by alopecia (Beco et al., 2013a).  
Primary predisposing diseases including immunodeficiencies, primary skin allergies, parasitic 
infestation, metabolic diseases, endocrinopathies and long-term treatment with corticosteroids 
have been associated with dermatological infections (Beco et al., 2013a; Green, 2012). 
Hypersensitivity reactions stimulated by allergens leading to inflammatory cell infiltration create 
conditions favorable for the development of dysbiosis, including overgrowth of S. 
pseudintermedius (Pierezan et al., 2016). A number of risk factors have been discussed in canine 
skin compared to other species including thin skin structure, compact stratum corneum, the 
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relative paucity of intercellular lipids in the stratum corneum, the lack of a lipid squamous 
epithelial plug at the entrance of canine hair follicles, and a relatively high pH (Green, 2012).  
Otitis externa is a common disease in dogs, with S. pseudintermedius being the most common 
bacterial cause of these infections in dogs (Bannoehr and Guardabassi, 2012). These infections 
are frequently polymicrobial and often complicated, as they often occur as secondary infections 
in animals with predisposing conditions as described above (Green, 2012). Bacterial otitis 
externa is not as common in cats as dogs, perhaps due to a straight ear canal and the lack of long 
ear pinna (Green, 2012).  
 
1.2.4 Urinary tract infections (UTI) 
Bacterial urinary tract infections (UTI) are common in dogs, with 14% of dogs visiting a 
veterinarian for UTI at least once in their lifetime (Ling, 1984; Thompson et al., 2011). Of dogs 
with a UTI, 4.5% are reported to have an unsatisfactory response to the prescribed treatment, 
resulting in recurrent or persistent infections (Thompson et al., 2011). Clinical signs of UTI in 
dogs consist of stranguria, pollakiuria, pigmenturia and hematuria (Thompson et al., 2011). 
Because these clinical signs are non-specific, urine culture for the isolation and identification of 
bacteria are the gold standard for the identification of UTIs (Brloznik et al., 2016; Dowling, 
1996). The collection of urine for culture is best done by cystocentesis which allows samples to 
be collected while minimizing contamination with feces and the microbial communities in the 
lower urinary tract. The isolation of Staphylococcus spp. in canine diagnostic submissions varied 
from 11-32.8% (Windahl et al., 2014). Staphylococcus pseudintermedius frequently cultured 
from these UTI (Maaland and Guardabassi, 2011). Polymicrobial infections including both Gram 
positive and negative bacteria are frequently reported in canine UTI (Windahl et al., 2014). Other 
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staphylococci including S. epidermidis, S. simulans, S. schleiferi ssp. schleiferi, S. aureus, S. 
schleiferi ssp. coagulans and S. saprophytic have been reported as coinfected with S. 
pseudintermedius in canine UTI (Penna et al., 2010). 
Urinary tract infections in dogs can be categorized as uncomplicated or complicated. 
Uncomplicated infections are defined as those in a structurally and physiologically normal 
urinary tract by non-resident organisms, while complicated infections occur in animals with 
anatomical, physiological and ongoing clinical manifestation or treatment failure (Weese et al., 
2011). Canine UTIs are most often ascending infections from the lower urinary tract, although 
hematogenous spread from distant body sites is also recognized (Thompson et al., 2011).  
Factors predisposing dogs to UTI can be divided into three main categories: 1. anatomical 
defects, 2. metabolic disorders and 3. iatrogenic. Anatomic defects may include ectopic ureters, 
females with recessed vulvas, persistent vaginal membranes or other causes of urine pooling 
which lead to ascending UTI. Metabolic diseases including diabetes mellitus and 
hyperadrenocorticism cause secondary immunosuppression and susceptible to various secondary 
bacterial infections including S. pseudintermedius. Other diseases such as chronic kidney 
disease, urolithiasis or bladder neoplasia also predispose to UTI by impairing host defense 
mechanisms including the disruption of mucosal integrity, presence of a nidus for bacterial 
growth and by affecting a dogs ability to appropriately concentrate urine (Green, 2012). Finally, 
iatrogenic factors such as glucocorticoid therapy, immunosuppression, complications from 
surgery, urinary catheterization, untreated perivulvar lesions may also predispose patients to UTI 
(Brloznik et al., 2016; Thompson et al., 2011)  
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1.2.5 Pharmacological considerations for therapy 
Skin infections are the main reason for the systemic application of antibiotics in canine practice 
(Beco et al., 2013a). Amoxicillin, first-generation cephalosporins, tetracycline, and sulfa-
trimethoprim are the first choices for treating Gram positive infections in companion animals 
(Prescott et al., 2002). Amoxicillin, cefalexin, cefovecin, and clindamycin were most prescribed 
antimicrobials for canine pyoderma in the UK (Summers et al., 2014). Selection of the 
appropriate antimicrobial requires the integration of patient data, antimicrobial susceptibility of 
the pathogen and pharmacokinetic and pharmacodynamics characteristics of the antimicrobial 
agent. The skin is the largest organ but has a relatively poor vascular supply compared to other 
organs such as the liver or kidneys (Beco et al., 2013b). In deep pyoderma, extensive necrosis 
and scarring with tissue debris limits penetration of antimicrobials into deep tissue, requiring the 
selection of drugs with good tissue penetration and the use of high doses are therefore often 
required (Beco et al., 2013b). Lipophilic antimicrobials such as clindamycin and doxycycline 
have better penetration into deep tissues compared with more hydrophilic drugs and may be good 
options for treating deep pyoderma (Nguyen et al., 2014). High doses are recommended with the 
presence of necrosis in dermatological infections in dogs (Beco et al., 2013b).  
Many antimicrobials, including the β-lactams, are eliminated at least partially by renal excretion, 
leading to high concentrations in the urinary bladder. The extent to which a drug is excreted 
through the renal tubules is dependant upon the hydrophilicity of the compound. Drug families 
including beta-lactams, quinolone, fosfomycin, nitrofurantoin, and chloramphenicol are excreted 
through renal tubules and reach a bactericidal or bacteriostatic concentration in the urinary 
bladder (Green, 2012).  
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1.2.6 Treatment options for Staphylococcus pseudintermedius clinical infections 
Superficial pyoderma is often empirically treated using non-antimicrobial options including 
shampoos, solutions which contain biocides such as chlorhexidine, triclosan and benzoyl 
peroxide (Clark et al., 2015; Loeffler et al., 2011; Valentine et al., 2012). One study found that 
the use of 4% chlorhexidine for treating superficial pyoderma performed similarly to systemic 
antimicrobial therapy (Bajwa, 2016). Oftentimes, a combination of systemically administered 
antibiotics and topical biocides are used for superficial canine pyoderma (Frank and Loeffler, 
2012). 
Guidelines for antimicrobial treatment of skin infection have been published by expert groups 
such as the International Society for Companion Animal Infectious Diseases (ISCAID), as well 
as clinical reviews describing therapeutic strategies for dermatological infections in small 
animals (Bajwa, 2016; Hillier et al., 2014; Loffler and Macdougall, 2007; Summers et al., 2012). 
These guidelines describe both topical and systemic application of antimicrobial for superficial 
folliculitis in dogs (Hillier et al., 2014). Topical treatment alone is only recommended in cases of 
surface pyoderma (Hillier et al., 2014). Moreover, the selection of systemic antimicrobials 
depends on the result of antimicrobial susceptibility tests, availability, safety, the cost of 
treatment and host-specific factors such as immunosuppression (Hillier et al., 2014). 
In uncomplicated UTI, both beta-lactams and sulfa-trimethoprim are used as first-line therapy 
(Weese et al., 2011). When treating complicated UTI, therapy must address underlying 
conditions such as diabetes mellitus or hyperadrenocorticism. A thorough laboratory 
investigation including complete blood count, biochemical profiles, and imaging together with 
antimicrobial susceptibility testing may be warranted (Weese et al., 2011). A working group 
from ISCAID has published treatment recommendations for short-term (3-5 days) and long-term 
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(14 days) antimicrobial treatment strategies for both uncomplicated and complicated UTI 
(Dowling, 1996; Jessen et al., 2015; Weese et al., 2011). In complicated UTI, relapse (recurrent 
infection within 6 months after therapy) and refractory infections (microbes are positive 
persistently) are common necessitating additional investigation to allow the inciting cause to be 
identified and addressed (Jessen et al., 2015).  
Identification and management of underlying conditions is an essential part of clinical success in 
both dermatological and UTI (Green, 2012). Moreover, clinical success is dependent upon 
multiple factors beyond antimicrobial susceptibility including the severity of infection and host 
immune status. Although  variety treatment strategies have been described for uncomplicated 
UTIs and dermatological infections, in our region insufficient data has been published on the 
antimicrobial susceptibility of this organism to make evidence-based empiric therapeutic 
decisions. 
  
1.3 Overview of antimicrobial resistance 
Antibiotics are low molecular weight compounds which inhibit microbial growth at low 
concentrations (Martens and Demain, 2017). Antimicrobials have been used to treat bacterial 
infections for the last 70 years. At present, an estimated 17 million people die every year from 
bacterial infections and the burden of antimicrobial resistance is increasing (Martens and 
Demain, 2017). In the United States, it is estimated that there are two million infections and 
23,000 deaths caused by antimicrobial-resistant organisms every year (CDC; Martens and 
Demain, 2017). Antibiotics are commonly prescribed drugs for bacterial infections and global 
antibiotic consumption has increased by 36% between 2010 and 2000 (Van Boeckel et al., 2014). 
A 2014 report commissioned by Wellcome Trust and the government of the UK with the aim of 
17 
 
estimating the emergence of antimicrobials resistance gained international attention. The authors 
of this report projected that mortality attributable to resistant bacterial infections will reach 10 
million in 2050, which will surpass mortality caused by cancers (O'Neill, 2016).  
In addition to mortality, antimicrobial resistance is also associated with increased health care 
costs. This has been best described in the case of S. aureus where the cost of treating patients 
with MRSA is higher than those infected with methicillin susceptible strains. In Spain, one study 
found that bacteremia caused by MRSA was 1.12-fold more expensive than MSSA to treat due 
to an additional 2.2 days of hospitalization and admission to intensive care units (Rubio-Terres et 
al., 2010). In the United States, the attributed mean cost per bacteremia in a patient with MRSA 
has been estimated to be $23,000, while MSSA infections have been estimated to cost $19,500 
(Paladino, 2000). In addition, resistance associated mortality in bloodstream infections with 
MRSA was found to be 3 fold higher than susceptible strains (Coulter et al., 2017). In 
companion animal practice, the effect of resistance on mortality, length of hospitalization and 
cost of care has not been adequately assessed. In veterinary medicine, a similar evaluation for the 
contribution to increased healthcare costs and mortality of antimicrobial resistance has not been 
conducted.  
Antimicrobial resistance can be categorized broadly as intrinsic or acquired (Giguere et al., 
2013). Intrinsic resistance is defined as an innate characteristic of a bacterial species which 
protect against an antimicrobial due to own structural and biochemical properties, resistance to 
antimicrobials, even in unselected populations is ubiquitous (Leclercq, 2013). Selection of 
resistant organisms occurs as a natural response of bacteria to a hostile (antimicrobial containing) 
environment (Qekwana et al., 2017; Saputra et al., 2017). Resistance is a natural phenomenon,  
in S. aureus resistance to penicillin was reported a just a few years after its introduction, 
18 
 
similarly, resistance to all currently available antimicrobials already exists in nature (Lobanovska 
and Pilla, 2017).  
 
1.3.1.1 The general mechanisms of antimicrobial resistance  
Resistance to antimicrobials occurs by four main mechanisms: 1. decreasing the permeability of 
cell wall, 2. increased efflux of the drug, 3. enzymatic inactivation and 4. modification or 
protection of drug targets (Giguere et al., 2013). 
Decreased cell permeability is a well-recognized mechanism of resistance among Gram 
negatives including non-fermenters such as Pseudomonas aeruginosa and E. coli, where 
resistance to the aminoglycosides and carbapenems has been reported to result from porin 
deficiencies in the cell wall (Dantas et al., 2017; Goessens et al., 2013; Mingeot-Leclercq et al., 
1999). Resistance to the 3rd generation cephalosporin, ceftazidime, in Klebsiella pneumonia due 
to Ompk35 and Ompk36 deficiencies have also been reported in clinical isolates (Wassef et al., 
2015).  
Efflux pumps in the cell membrane can also result in resistance by reducing the intracellular 
antimicrobial concentration below an inhibitory level (Li, 2004). Several classes of multi-drug 
resistance efflux pumps have been described including major facilitator superfamily MDR efflux 
pump, small multidrug resistance family MDR efflux pumps, multi drug and toxin extrusion 
family MDR efflux pumps, resistance nodulation division family efflux pumps and the ATP-
binding cassette family MDR efflux pumps (Schindler and Kaatz, 2016). Efflux-mediated 
resistance is common for the sulfamethoxazole, tetracycline, and fluoroquinolone drug classes 
(Schindler and Kaatz, 2016). In Gram-positives including S. aureus and S. pseudintermedius, 
efflux pumps are either chromosomal or plasmid encoded (Costa et al., 2013).  
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Antibiotic modification enzymes can be classified into four major families including hydrolases, 
group transferase, redox enzymes and lyases which inactivate the beta-lactams, aminoglycosides, 
chloramphenicol, and tetracyclines respectively (Schroeder et al., 2017; Wright, 2005).The β-
lactamases are a very common cause of resistance to β-lactams in both Gram positive and Gram 
negative bacteria (Dever and Dermody, 1991). These enzymes may be excreted, or in the case of 
some enzymes in Gram negative bacteria remain in the periplasmic space (Dever and Dermody, 
1991). The aminoglycoside group transferases (N-acetyltransferases, nucleotide transferases, and 
phosphotransferases) alter the structure of these drugs, inactivating them19 (Mingeot-Leclercq et 
al., 1999; Ramirez and Tolmasky, 2010). A similar mechanism was found for chloramphenicol 
where both acetyltransferase and phosphotransferase inactivating enzymes have been described 
(Fernandez et al., 2012).  
Alteration of the antimicrobial target has been shown to confer resistance to a number of drug 
classes including the β-lactams, fluoroquinolones, sulfonamides, and trimethoprim (Giguere et 
al., 2013). Resistance can also result from the overproduction of a drug target, allowing cellular 
metabolic functions to continue despite the presence of an antimicrobial. One example of this is 
the dfr mediated overproduction of dihydrofolate reductase which confers resistance to 
trimethoprim (Brolund et al., 2010). Similarly, sulfonamide resistance can result from the 
hyperproduction of para-aminobenzoic acid (PABA), which competitively excludes the 
incorporation of sulfonamide drugs and restores folate synthesis (Then, 1982).  
 
1.3.1.2 General mechanism of acquiring resistance 
Bacteria acquire resistance by four general mechanisms: 1. mutation, 2. transformation, 3. 
transduction and 4. Conjugation (Giguere et al., 2013). A mutation is a random event during 
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DNA replication; when mutants result in resistance they may confer a fitness advantage and 
therefore be selected for on exposure to antimicrobials. Specific mutations leading to resistance 
to fluoroquinolone and tetracycline antimicrobials has been observed; single nucleotide 
polymorphisms (SNPs) in the gyrA gene are shown to result in fluoroquinolone resistance in 
E.coli (Kogaluru Shivakumaraswamy et al., 2017). Similarly, 16S rRNA mutations have been 
shown to lead to tetracycline resistance in Propionibacterium acne (Ross et al., 1998). In some 
cases, mutational resistance has been shown to develop as a response to long-term exposure to 
non-lethal antimicrobial doses; for instance, Mycobacterium tuberculosis undergoes a high rate 
of mutation leading to resistance (Andersson and Hughes, 2012). 
Entire resistance genes may also be introduced into a bacterium. The three primary mechanisms 
of gene acquisition are transformation (acquiring free DNA from dead cells), transduction 
(bacteriophages), and conjugation/horizontal transfer from other bacteria (plasmids and other 
mobile genetic elements) (Giguere et al., 2013; Schroeder et al., 2017). Horizontal gene transfer 
is the most common mechanism for the acquisition of foreign resistance genes and has been 
shown to be particularly common in polymicrobial infections (Champness, 2007; Schroeder et 
al., 2017). These mobile genetic elements may contain multiple antimicrobial resistance and 
virulence genes and may be broadly transmissible or limited to a species (Schroeder et al., 2017). 
Dissemination of resistance genes in S. pseudintermedius has been shown to occur by transposon 
conjugation, transduction, and transformation (von Wintersdorff et al., 2016). One key example 
is the Staphylococcal Chromosomal Cassette (SCC) element which contains both virulence and 
resistance genes.   
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Figure 1.1: Antimicrobial susceptibility testing techniques 
A: disk diffusion test, B: gradient strip test, C: agar dilution test, D: broth dilution test/micro 
broth 
  
22 
 
1.3.2 Summary of antimicrobial susceptibility testing 
A number of laboratory methods have been developed to evaluate an antibiotic against selected 
microbes in vitro. Antimicrobial susceptibility testing follows a meticulously standardized 
protocol in the current diagnostic laboratory (Giguere et al., 2013). Standardized methods were 
initially introduced by Bauer et al in 1966, and have subsequently developed into our modern 
methods (Jorgensen and Ferraro, 2009; Matuschek et al., 2013). Standardization of protocols is 
critical to ensure that results are reproducible and reliable, two main international standards are 
recognized: The Clinical and Laboratory Standards Institute (CLSI), and the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) (CLSI, 2016; EUCAST, 2017). 
The standardization of antimicrobial susceptibility testing includes every step of the protocol 
including inoculum concentration, media, antibiotic disk concentration, incubation time and 
temperature and control bacterial strains. Test methods can be categorized as being based on 
diffusion or dilution (Figure 1.1).  
 
1.3.2.1 Diffusion-based methods  
The diffusion-based methods include the disk diffusion and gradient strip tests (Figure 1.1). To 
perform these assays, a fresh McFarland 0.5 bacterial suspension (approximately 108 CFU/ml) is 
seeded on 4 mm thick Mueller-Hinton agar. After the plate is inoculated, a disk or strip 
impregnated with an antibiotic is placed on the agar and incubated at 35°C for 18-24 hours 
(Balouiri. et al., 2016). A concentration gradient developed radially with high drug concentration 
immediately surrounding the disk and decreasing outwards. Bacteria grow only up to the 
maximum concentration they tolerate resulting in an inhibitory zone where no bacteria grow 
surrounding the disk. The diameter of the inhibitory zone is measured and interpreted according 
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to a standard set of criteria laid out by the CLSI or EUCAST (CLSI, 2010; EUCAST, 2017). The 
disk diffusion is the oldest method to be standardized and is the simplest test method (Jorgensen 
and Ferraro, 2009). The disk diffusion methods provide a qualitative description of susceptibility 
(categorizing isolates as susceptible, intermediate or resistant). This technique is a cost-effective 
means for screening the most common human and animal bacterial pathogens (Matuschek et al., 
2013). This method has the advantage of not requiring special equipment, is simple to interpret 
and allows antimicrobial panels to be easily customized. However, this method is not suitable for 
certain fastidious bacterial species, limiting its application to common, aerobic pathogens 
(Jorgensen and Ferraro, 2009). 
The gradient strip method (eg. E-test) is a hybrid diffusion-dilution assay where an antimicrobial 
gradient is impregnated into strips with high concentrations at one end and low at the other end 
(Balouiri. et al., 2016) (Figure 1.1). Agar plates (Mueller-Hinton) are inoculated as per the disk 
diffusion test, and following incubation the MIC is read “at the intersection of the strip and 
growth inhibition ellipse” (Balouiri. et al., 2016). Like disc diffusion testing this method is 
simple to perform and customization of antimicrobial test panels is easy. Unfortunately, the 
advantages of this method are offset by the relatively unreliable data generated compared to 
dilution based methods for determining MIC (Balouiri. et al., 2016; Jorgensen and Ferraro, 
2009).  
 
1.3.2.2 Dilution based methods  
Dilution based antimicrobial susceptibility testing can be done in either and agar or broth-based 
media. In agar dilution, Mueller-Hinton agar plates are prepared with serial dilutions of 
antimicrobials and a standard bacterial inoculum (107) is spotted on the agar (Jorgensen and 
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Ferraro, 2009). The plate containing the lowest antimicrobial concentration where no growth is 
observed is the MIC. Although this method is technically simple to perform and has low reagent 
costs, it is laborious and requires large quantities of incubator space which limit its routine 
application in diagnostic settings.  
Similar to agar dilution, broth dilution consists of a series of antimicrobial concentrations 
prepared in Mueller-Hinton broth. Broths are then inoculated to a standard bacterial density 
prepared from a 0.5 MacFarland suspension. This test can be carried out in 96 well microtitre 
plates (micro broth dilution) or in larger tubes (macro broth dilution). Following inoculation, the 
broth is incubated at 350C for 18-24 hours. The MIC is defined as the minimum concentration 
which completely suppresses the growth of bacteria, observed either as a lack of turbidity of lack 
of a cell pellet in each well or tube (CLSI, 2012a; Giguere et al., 2013).  
 
1.3.2.3 Interpreting test results 
Following a susceptibility test, clinical breakpoints are used to categorize isolates into one of 
three possible groups: susceptible, intermediate or resistant (CLSI, 2013). Because clinical 
breakpoints are designed to predict clinical outcome, they integrate microbiological data with the 
pharmacokinetic and pharmacodynamics properties of a drug (CLSI, 2012a, b; Giguere et al., 
2013). The susceptible and resistant isolates has been defined by CLSI (M07-A9: Methods for 
dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-
Ninth edition, 2012) (CLSI, 2012a). Drugs to which an organism is intermediately susceptible to 
may be used if the animal can be treated with a high dose, although toxicity may be limiting. 
For S. pseudintermedius, clinical breakpoints have only been developed for ampicillin, oxacillin, 
cefoxitin, cephalosporins, cefazolin, cefpodoxime, pradofloxacin and doxycycline (CLSI, 2015). 
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These clinical breakpoints have only been described for skin and soft tissue infections, 
breakpoints specific to other clinical diseases have not been published in the guideline (CLSI, 
2015). For other drugs, veterinary breakpoints for other staphylococci are often used for 
interpretation including amikacin, tetracycline, clindamycin, enrofloxacin, marbofloxacin, 
orbifloxacin, difloxacin and amoxicillin-clavulanate (CLSI, 2015). In the absence of veterinary 
breakpoints, human clinical breakpoints for Staphylococcus aureus are used for gentamicin, 
rifampin, sulfisoxazole, trimethoprim-sulfamethoxazole, vancomycin, erythromycin, 
chloramphenicol, quinupristin/dalfopristin, linezolid and nitrofurantoin (CLSI, 2015). For 
daptomycin and tigecycline, only EUCAST breakpoints for S. aureus are available, although 
these drugs are not used in companion animals (EUCAST, 2017).  
When clinical breakpoints are not available, epidemiological cut-offs which are based on the 
population distribution of MICs can be used to identify bacteria possessing acquired resistance 
mechanisms. Isolates are categorized as either wild-type or resistant, isolates with MICs within 
normal distribution are defined as wild-type while those MICs above are defined as resistant 
(Morrissey et al., 2014). Importantly, the concept of epidemiological cut-off came up as the 
maximum possible MIC among wild isolates and considered as lack of acquired resistance in 
those isolates collection (Ängeby. et al., 2011). Isolates with MICs higher than ECOFF are 
assumed to possess some form of acquired resistance (e.g. mutational or a novel resistance gene) 
(Ängeby. et al., 2011). Although there is not necessarily an association between epidemiological 
cut-offs and clinical breakpoints of an organism, epidemiological cut-offs are useful for detecting 
emerging resistance (Ängeby. et al., 2011).  
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1.3.3 Antimicrobial resistance Staphylococcus pseudintermedius 
1.3.3.1 Emergence of resistance 
Antimicrobial resistance limits the ability of clinicians to select appropriate antimicrobials for the 
treatment of bacterial infections. Among S. pseudintermedius, resistance is emerging to the β-
lactams, with resistance to penicillin reported in over 70% of S. pseudintermedius isolates 
colonizing healthy dogs and ~95% of clinical isolates (Bean and Wigmore, 2016; Kang et al., 
2014; Yoon et al., 2010). A recent systemic review found that between 1980 and 2013 there was 
a trend of increasing resistance to penicillin and ampicillin among methicillin susceptible S. 
pseudintermedius (MSSP) (Moodley et al., 2014). Resistance to other classes including the 
fluoroquinolones, aminoglycosides, and chloramphenicol also increased during that period 
(Moodley et al., 2014). Interestingly, this review found that there was no significant difference in 
the frequency of resistance to non--lactams between methicillin resistant and susceptible 
isolates (Moodley et al., 2014). Alarmingly, resistance to amikacin which is used as last line 
therapy for treating MRSP infections in dogs is emerging and was recently identified in 37% of 
MRSP in the United States (Gold et al., 2014). In the Saskatoon region, MRSP was not identified 
in the baseline resistance surveillance study conducted in 2008 (Rubin and Chirino-Trejo, 2011). 
Subsequently, MRSP was identified from clinical cases in Saskatoon including a dog with 
necrotizing fasciitis and another with a UTI (Mayer and Rubin, 2012; Rubin and Gaunt, 2011a). 
Fortunately, resistance to last line of defense drugs (e.g. vancomycin or linezolid) used for 
treating resistant Gram-positive infections in humans has not been reported in S. 
pseudintermedius. Continued resistance surveillance targeting healthy dogs will be useful for 
detecting the emergence of resistance in the community. However, methodological 
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inconsistencies between studies including site and number of samples collected and media used 
to isolate S. pseudintermedius make the identification of global resistance trends difficult.  
Methicillin resistant S. pseudintermedius first emerged in the late 1990s in Europe and North 
America and is increasingly reported globally (Bean and Wigmore, 2016; Damborg et al., 2016; 
Hensel et al., 2016; Kasai et al., 2016; Weese and van Duijkeren, 2010). From 2004 through 
2013, the incidence of canine MRSP infections increased sevenfold at a veterinary diagnostic lab 
in Utrecht, the Netherlands (Duim et al., 2016). Colonization of 0-30% of healthy dogs with 
MRSP has been reported, and this organism has also been isolated from cats and people (Bean 
and Wigmore, 2016; Gomez-Sanz et al., 2011; Gronthal et al., 2015; Kjellman et al., 2015; 
Weese, 2010). Among diagnostic submissions, MRSP has reportedly been recovered from 5-
66% of clinical submission from dermatological, otitis externa and UTI samples (Gold et al., 
2014; LoPinto et al., 2015; Maluping et al., 2014; Windahl et al., 2012; Zur et al., 2016). Two 
main epidemic clones of MRSP are recognized, ST68 and ST71in North America and Europe 
respectively (van Duijkeren et al., 2011b). Both ST68 and ST71 frequently carry multiple 
resistance genes for tetracycline, quinolone, trimethoprim, aminoglycoside, macrolide, and 
lincosamide (McCarthy et al., 2015). Interestingly, MRSP in North America are reportedly often 
susceptible to chloramphenicol while isolates from Europe are frequently resistant (van 
Duijkeren et al., 2011b). More recently reports of high rates of resistance to chloramphenicol 
have suggested the emergence of a new MDR clone of MRSP in USA (Videla et al., 2017). 
Multi-drug resistant S. pseudintermedius (MDRSP) has also been increasing; in one study 62% 
of clinical isolates MRSP from dogs were MDR, resulting in very limited treatment options 
(Vigo et al., 2015; Zur et al., 2016). Other studies have reported that among 3%-27.5% are MDR 
(Detwiler et al., 2013; Garbacz et al., 2013). 
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Epidemiological studies have been done to identify risk factors for dogs to be infected with 
MRSP including previous antimicrobial therapy surgical interventions, duration of 
hospitalization, lack of decolonization strategy (Karanika et al., 2015; Sganga et al., 2016). 
Exposure to fluoroquinolones and β-lactams in the past month and long-term treatment with β-
lactam drugs was identified as a risk factor for MRSP infection (Faires et al., 2010; Zur et al., 
2016). Another study found that prior hospitalization and antibiotic exposure within the previous 
6 months were risk factors (Nienhoff et al., 2011). The risk factors for colonization of MRSP in 
dogs have been studied to a limited extent; positive correlations between the number of 
veterinary visits, hospitalization, administration of glucocorticoids and topical antimicrobials, or 
being a breeding female were found (Gronthal et al., 2015; Lehner et al., 2014). In addition, 
Lloyd highlighted close contact with carriers or infected animals, ongoing invasive infections or 
surgical procedures as risk factors for MRSP colonization (Lloyd, 2010).  
 
1.3.3.1.1 Methicillin resistance 
Methicillin resistance is identified by using either cefoxitin or oxacillin susceptibility as an 
indicator (van Duijkeren et al., 2011a). When determining an isolates susceptibility to oxacillin, 
2% NaCl must be added to the media (CLSI, 2017). For S. pseudintermedius, oxacillin testing is 
preferable to cefoxitin. MRSP isolates are frequently artifactually susceptible to cefoxitin in 
vitro, resulting in a high percentage of false negatives and the failure to detect methicillin 
resistance (Wu et al., 2016). PCR detection of mecA is recommended to confirm methicillin 
resistance identified by phenotypic tests (van Duijkeren et al., 2011a).  
Gram-positive bacteria are covered by a thick layer of peptidoglycan which consists of short 
glycan chains of N-acetylmuramic acid and 1-4-N-acetyl glucose amine residues (Stapleton, 
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2002). The pentaglycine cross-bridges are cross-linked or transpeptidation occurs in the 
cytoplasmic membrane and which is catalyzed by the penicillin binding protein (PBP) 
(Stapleton, 2002). The beta-lactams inhibit transpeptidase activity by D-alanyl-D-alanyl bonds of 
stem peptide. However, beta-lactams have a weak affinity towards PBP2a found in methicillin 
resistant staphylococci (Stapleton, 2002). The serine binding site of PBP2a is less accessible to 
β-lactams due to a narrow-extended cleft compared to other PBPs (Peacock and Paterson, 2015).  
The mecA gene which is the “classical gene” conferring methicillin resistance was discovered in 
1986 (Becker et al., 2014). Later, mecC was found in MRSA playing a similar role as mecA 
among livestock and human isolates in Europe (Garcia-Alvarez et al., 2011). Furthermore, mecB 
were identified in Macrococus caseolyticus in Japan (Becker et al., 2014). Recently, mecD 
possessing M. caseolyticus from bovine and canine sources were identified although the risk of 
this novel methicillin resistance determinant for companion animals need to be investigated 
(Schwendener et al., 2017).  
In Staphylococci, the mec family of genes encode for altered penicillin-binding proteins in the 
cell wall (Peacock and Paterson, 2015). The mecA gene was originally found in the 
Staphylococcal chromosomal cassette (SCC) complexes of coagulase-negative Staphylococcus 
sp. (Zong and Lu, 2010). The SCC is a mobile genetic element which facilitates integration into 
the chromosome and allows horizontal gene transfer (Peacock and Paterson, 2015; Sjostrom et 
al., 1975). Expression of mecA is regulated by mecR1 and mecI which are co-located in the SCC 
close to mecA gene, this complex of mec genes within the SCC is referred to as the “SCCmec” 
(Peacock and Paterson, 2015; Stapleton, 2002).  
Altogether 12 SCCmec types (I – XII) have been described, SCCmec II-III, IV, V, and VII are 
the most common in S. pseudintermedius (Chanchaithong et al., 2016). Between types, the size 
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of the SCCmec varies between 21-67kb; different types may contain different genes for 
integration, chromosome recombinase and the “J region” which houses additional antimicrobial 
resistance genes (Peacock and Paterson, 2015). The SCCmec complex can excise from the 
chromosome and then reintegrate into the chromosome of another organism by excision gene 
called ccrA and ccrB which in SCCmec complex (Zong and Lu, 2010). Within the SCCmec 
complex, there is evidence of a number of mobile genetic elements including insertion 
sequences, transposons, integrated plasmids and unknown functional genes (Zong and Lu, 2010). 
The SCC elements are involved in the acquisition of multiple resistance genes in Staphylococcus 
including S. pseudintermedius (McCarthy et al., 2015; Zur et al., 2016). As an example, SCCmec 
type II-III are found in hospital-acquired MRSP with multiple resistance genes (Zur et al., 2016). 
 
1.3.3.1.2 Mechanisms of resistance to tetracycline 
Acquired resistance to tetracyclines has been reported by four different mechanisms: 1. the 
production of ribosome protection proteins, 2. efflux, 3. enzymatic inactivation of the drug and 4.  
mutation in genes encoding the 16S rRNA or the small subunit ribosomal protein (Chopra and 
Roberts, 2001). Although a large number of tetracycline resistance genes have been identified, 
only four genes (tetK, tetM, tetO, tetL) have been previously reported in S. pseudintermedius 
(Kadlec and Schwarz, 2012). The tetK and tetL genes encode tetracycline specific efflux pumps 
belonging to the major facilitator superfamily (MFS) of efflux pumps, in staphylococci, these are 
commonly found on plasmids (Chopra and Roberts, 2001; Khan and Novick, 1983). The tetK 
gene is found in both Gram positive and negative bacteria including S. aureus and E. coli 
(antibiotic resistance gene database: ardb.cbcb.umb.edu) (Adefisoye and Okoh, 2016). The tetL 
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gene has also been found among a variety of bacterial genera including Streptococcus, 
Actinocbacillus, Lactobacillus, and Mannheimia (Chopra and Roberts, 2001). 
The tetM and tetO encode for the ribosomal protection proteins in Staphylococci (Kadlec and 
Schwarz, 2012). Both tetO and tetM are found in a wide host range including Gram-negative and 
Gram-positive bacteria (Chopra and Roberts, 2001). The antibacterial activity of tetracycline is 
due to preventing the binding of the aminoacyl-tRNA to ribosomal-mRNA complex which halts 
protein synthesis (Chopra and Roberts, 2001). Ribosomal protection proteins confer tetracycline 
resistance by binding to the aminoacyl-tRNA complex and displacing tetracycline from the 
ribosome (Chopra and Roberts, 2001). In S. pseudintermedius, tetM is the most commonly found 
tetracycline resistance gene (Kadlec and Schwarz, 2012). The tetM gene has been found in both 
the Tn916 and Tn5801 transposons which are integrative and conjugative elements (ICE) (de 
Vries et al., 2016). These conjugative transposons have a broad host range and have also been 
shown to play a role in the dissemination of chloramphenicol, kanamycin, and erythromycin 
resistance genes (Chopra and Roberts, 2001; de Vries et al., 2016).  
The tetracyclines can be inactivated by tetX, tet34, tet37 and tetU although these genes have not 
been reported in Staphylococci (Thaker et al., 2010). Mutational resistance involving SNPs in the 
small subunit RNA and the S12 ribosomal protein which facilitate interaction between 
tetracycline and ribosome are also recognized (Chopra and Roberts, 2001; Nguyen et al., 2014). 
Multidrug resistance efflux pumps including those in the ABC, MFS, and MATE have been 
reported to include tetracycline as a substrate in other Gram-positive bacteria, although their role 
in S. pseudintermedius has not been studied (Schindler and Kaatz, 2016).  
At present, the Clinical Laboratory Standard Institute (CLSI) recommends using tetracycline as 
an indicator drug to screen resistance to doxycycline, minocycline. The guideline also states that 
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isolates which possess intermediate resistance to tetracycline may susceptible for doxycycline 
(CLSI, 2017). However, because doxycycline and tetracycline have different chemical properties 
they may not necessarily interact with bacteria identically (Nguyen et al., 2014). Moreover, 
doxycycline and minocycline are lipophilic and were shown to bind with the ribosome with 
higher affinity than tetracycline (Nguyen et al., 2014). The correlation of resistance between 
these three drugs is ill-defined and the contribution of recognized resistance genes to phenotypic 
resistance has not been evaluated.  
 
1.3.4 Identification of novel resistance mechanism  
Next generation sequencing is an emerging technique for the identification of new antimicrobial 
resistance genes. The rapid advancement of techniques with decreasing analytical turnaround 
time and diminishing cost has increased the availability of this method to identify novel resistant 
determinants in bacteria. Moreover, new easier to use bioinformatic tools including “Geneious” 
and “CLC viewer” greatly facilitate quality checking and de-novo assembly. Genomes can be 
annotated using free online tools, resistance genes can be readily identified using a number of 
curated, searchable online databases such as CARD, ResFinder, ARDB, MEGARes and 
RESFAMS which already contain more than 13,000 antibiotic resistant determinants (Gordon et 
al., 2014; Jia et al., 2017; Kwong and McCallum, 2015; Zankari et al., 2012; Zhao et al., 2016). 
These tools allow researchers from the biological sciences to meaningful analyze genome 
sequences without advanced knowledge of computer programming. Recently, the role of WGS in 
the future of antimicrobial susceptibility testing was reviewed by a special committee of 
EUCAST with the aim of standardizing how genomic tools are used for identifying antimicrobial 
resistance (Ellington et al., 2017). 
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The advantage of WGS for the identification of new resistance genes is that it doesn’t necessarily 
require prior knowledge of the gene’s sequence as would be needed for targeted PCR based 
assays (Zhao et al., 2016). The identification of new genes relies on the comparison of genomes 
from organisms with susceptible and resistant phenotypes and it therefore essential to 
complement genomic approaches with classical phenotypic characterization. Furthermore, when 
unknown resistant phenotypes are being investigated, the next step is to identify and characterize 
the gene or mutation responsible for the phenotype. Once a genome is sequenced, the 
investigator is not limited to searching for resistance genes and mutations, but he or she can also 
look for variation in the genes promoter region or other nucleotide sequences which may affect 
expression. Once the sequence of a resistant gene is identified, the genomes of other organisms 
can be queried for this sequence. This strategy of resistance gene identification was exemplified 
by a recent study by Cavaco et al, who identified a novel linezolid-resistance gene in 
Enterococcus sp. in Colombia (Cavaco et al., 2017). The identification of resistance associated 
SNPs in the core genome has been used to forecast the emergence of resistance in bacteria. 
Finally, WGS is a valuable tool for detecting resistant genes from organisms which can not be 
cultured by conventional bacteriological methods.  
Whole genome sequence collections serve as a valuable data set which can be queried when 
novel resistance determinants are identified. As an example, following the publication of the 
sequence of the mobile colistin resistance (mcr-1) gene, which was recently identified in E. coli 
in China, mcr-1 was rapidly identified in different isolate collections around the world (Liu et al., 
2016).  
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1.4 Molecular epidemiology of Staphylococcus pseudintermedius 
1.4.1 Molecular epidemiological tools 
Molecular epidemiological tools are used to determine isolate relatedness or identify a common 
source of bacterial isolates in a given population at a particular time (ex. during an outbreak). 
Some techniques are based on DNA sequence analysis while others which compare banding 
patterns are indirectly based on sequence. A number of molecular tools used for characterization 
Staphylococcus spp. (Table 1.3) have been optimized for S. pseudintermedius (Solyman et al., 
2013). Each technique possesses its own resolving power, cost, availability of the global 
database, the requirement for specialized equipment and selection of the technique is based on 
the requirement and purpose of the study.  
There are a number of techniques specific to Staphylococci which are commonly used in 
molecular epidemiological investigations. Spa typing is one method which exploits the 
hypervariable region of “Staphylococcus Protein A” used for differentiating closely related 
strains (Sivaraman et al., 2009). The region consists of a number of polymorphic repeats, the 
region can be characterized using online databases available (seqnet.org, spaserver.ridom.de). 
The sequence is submitted to the database and assigned a spa type based on a comparison with 
previously deposited sequences. The Staphylococcus chromosomal cassette is the target region 
for the SCCmec typing which is classified as a hierarchical way with “types” and “subtypes”. 
The classification is based on ccr and mec gene complexes in SCC element and has been 
standardized internationally. SCCmec typing can be combined with other characterization 
methods including dru typing. The dru typing method is focused on direct repeat unit-variable-
number tandem repeat which is found in SCCmec element close to IS431(dru-typing.org). These 
40 base repeat sequences are searched in database and combination of repeats are taken (dru-
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typing.org). dru typing is a sequence-based method which has the advantage of interlaboratory 
reproducibility and relatively low cost (Kadlec et al., 2015). Since SCCmec is found in MRSP, 
both SCC mec typing and dru typing are only limited to characterize methicillin resistant isolates 
(Chanchaithong et al., 2014). These methods have been successfully used in investigations of S. 
pseudintermedius (Couto et al., 2016b; Kadlec et al., 2016). Band based techniques such as 
pulsed-field gel electrophoresis are also commonly used in large outbreaks, these techniques 
have relatively low reagent costs and due to their high-resolving power are useful for 
characterizing outbreaks (Rota et al., 2015). A combination of two methods, including one band 
based technique and one sequence-based method, together overcome the limitations of each 
technique, with high accuracy and reproducibility and interlaboratory comparison (Kadlec et al., 
2015).  
 
1.4.1.1 Pulse field gel electrophoresis 
Pulse field gel electrophoresis (PFGE) was once the gold standard for investigating outbreak 
investigations, although it is currently being replaced by WGS (Salipante et al., 2015). Briefly, 
genomic DNA is digested using restriction enzymes, resulting in variably sized fragments which 
can be resolved on a gel. Single nucleotide polymorphisms at restriction sites change the size of 
bands by eliminating or generating novel restriction sites resulting in fewer or lesser fragments. 
The resulting banding pattern is compared, and its similarity indicates how closely associated 
two isolates are.  
Performing PFGE is a labor-intensive process. In brief: bacterial DNA is digested using 
restriction enzymes, and fragments are resolved by gel electrophoresis. SmaI and Cfr9I are the 
most commonly used restriction enzymes for PFGE of S. pseudintermedius (Chanchaithong et 
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al., 2014). Following digestion, a specialized electrophoresis chamber which applies a current 
whose flow constantly changes direction, allowing large molecular weight DNA fragments to be 
separated. Electrophoresis can be done in a system such as the Bio-Rad CHEF-DRIII apparatus, 
following separation of DNA fragment the gel is stained for the visualization of bands with 
ethidium bromide. DNA fragments are then visualized under UV light and images are captured 
for analysis using software such as GelCompare. Banding patterns are then defined using the 
Dice coefficient and compared using the UPGMA algorithm to quantify the relatedness of 
isolates. Banding patterns are then compared, one set of criteria developed by Tenover et al., 
described four categories of relatedness that can be assigned to isolates: 1. indistinguishable, 2. 
closely related, 3. possibly related and 4. unrelated) (Tenover et al., 1995). 
Because PFGE banding patterns vary with polymorphisms throughout the entire genome, rather 
than at a particular locus or set of loci, the resolving power of this technique is high compared to 
other fingerprinting methods such as spa typing or MLST (Ohadian Moghadam et al., 2017). 
However, a limitation of this method is that without highly trained, specialized labor and the use 
of standardized protocols, the data generated by PFGE cannot be readily compared between 
laboratories (Salipante et al., 2015).  Staphylococcus pseudintermedius isolates have been 
compared with PFGE to identify transmission between dogs, and from dogs to humans 
(Chanchaithong et al., 2014; Gomez-Sanz et al., 2013c; Rota et al., 2015). PFGE is often 
performed in combination with other techniques including multi-locus sequence typing (MLST), 
SCCmec typing and spa typing (Chanchaithong et al., 2014).  
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1.4.1.2 Multilocus sequence typing (MLST) 
Multilocus sequence typing schemes have been developed for many bacterial species and data is 
available in open databases hosted many websites such as www.mlst.net, mlst.warwick.ac.uk and 
pubmlst.org. This method is based on comparing the sequences of ‘housekeeping’ genes unique 
to each bacterial species, for S. pseudintermedius a seven-housekeeping gene (ack, cpn60, fdh, 
pta, purA, sar, tuf) scheme has been developed (Solyman et al., 2013). Each unique allelic 
sequence is assigned a number, and the allelic profile defines the sequence type. As of April 12, 
2017, 733 sequence types have been assigned in S. pseudintermedius (Solyman et al., 2013). 
MLST provides an accurate, unambiguous, portable information useful for studies of bacterial 
evolution and global epidemiology (Solyman et al., 2013). However, the high cost of sequencing 
cost and relatively low resolving power are important limitations of this method. For MLST, 
each gene is PCR amplified followed by sequencing; allelic profiles are generated following 
submission of data to the appropriate database. Allelic profiles can be compared manually or 
utilizing algorithms such as eBURST, and relationships between isolates can be displayed as a 
dendogram or minimum spanning trees.  
MLST has been widely used for S. pseudintermedius, ST71 and ST68 have been reported to be 
epidemic clones in Europe and North America respectively (Perreten et al., 2010). More recently 
ST71 has been found more broadly and is now considered to be a globally epidemic clone 
(Gronthal et al., 2014). At present, there are no descriptions of ST68 in Western Canada although 
it is widely reported in the United States. The dissemination of these epidemic clones across 
borders is no doubt facilitated by the ease of international movement of people and animals. 
Globally, five major MRSP clonal complexes were identified by international study including 
isolates from all over the world in S. pseudintermedius (Pires Dos Santos et al., 2016). 
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Interestingly the SCCmec element of those clusters differed, suggesting that multiple 
recombination seem to be common in the genome of S. pseudintermedius genome (Pires Dos 
Santos et al., 2016).  
 
1.4.1.3 Whole genome sequencing (WGS) 
Recent technological advancements have made whole-genome sequencing a popular molecular 
epidemiological tool. DNA sequencing can be done using a number of technologies commonly 
described the first generation and next-generation sequencing. First generation sequencing 
technologies are relatively low throughput, allowing at most several hundred fragments to be 
sequenced simultaneously. These techniques include those developed by Maxam and Gilbert, 
and Sanger and were used extensively early in the era of genome sequencing (Choudhuri, 2014).  
Next generation technology is high-throughput and massively parallel allowing tens of thousands 
to billions of DNA fragments to be sequenced simultaneously allowing large amplicon libraries 
or fragmented whole genomes to be quickly sequenced. Bacterial genomes have been sequenced 
using a variety of platforms including Roch 454, Illumina and ABI SoliD (Choudhuri, 2014). 
Roche 454 was the first next-generation sequencing and commercially launched in 2005, which 
is single molecule improvement to the standard pyrosequencing (Choudhuri, 2014). In this 
method, sequencing libraries are amplified by emulsion PCR. Fragments or amplicons of up to 
800-1000 base pairs are sequenced following ligation of adapters which act as a universal 
priming sequence for both amplification/sequencing. In summary, this technique consists of 
DNA fragmentation and adapter ligation, one fragment-one bead complex formation, fragment 
amplification by em-PCR, purification and sequencing by synthesis (Choudhuri, 2014).  
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Illumina is the most widely used platform currently and introduced in 2008 (Choudhuri, 2014). 
Although both Illumina and Roche are described as sequencing by synthesis, Illumina utilizes 
fluorescent reversible terminator chemistry which eliminates issues with homo polymers as 
described in Roche 454 (Choudhuri, 2014). The technique consists of DNA library preparation, 
fixing to flow cells, bridge amplification, cluster generation and sequencing by synthesis 
(Choudhuri, 2014). The fluorescent is detected by CCD camera (Choudhuri, 2014). Furthermore, 
once DNA library is prepared, double-stranded DNA denatured and binds to the flow-cell 
channel by hybridizing adapters. After that, DNA clustered are made and the double-stranded 
bridge is formed followed by denatured into a single strand. Only forward strand remains in flow 
cell channel all reverse strands are washed away. The sequencing by synthesis occurs in those 
forward strands clustered, fluorescently labeled nucleotides are added individually and detected. 
The ABI SOLiD platform is based on the principle of sequencing by oligonucleotide ligation and 
detection (Choudhuri, 2014). In summary, this method consists of DNA library preparation, the 
formation of bead-fragment complexes, fragment amplification, purification, bead 
immobilization and sequencing by ligation (Choudhuri, 2014). A series of ligation cycles occurs 
(ligation, cleavage, and detection) and templates are reset for the following cycles by removing 
extension products, the fluorescent dye is used for detection of ligated base combinations 
(Choudhuri, 2014). Sequenced genomes can then be assembled de-novo, or mapped to a 
reference genome. The rapid advancement of sequencing technology has reduced the duration 
and costs of sequencing, while the initial human genomic project took years to complete at a cost 
of billions, the same data could now be generated in a matter of days for several thousand dollars 
(Collins et al., 2003).  
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WGS has applications in new pathogen identification, the design of diagnostic tests, molecular 
epidemiological investigations and improves our ability to estimate evolutionary time frames 
within bacterial populations (Lynch et al., 2016). Furthermore, identification of microbial 
organism which defined as slow-growing organism including non-tuberculous Mycobacterium 
and unusual disease presentations such as neuro leptospirosis occur by WGS (Kwong and 
McCallum, 2015). In addition, for patients with infections with a pathogen which is undetectable 
using routine tests (e.g. genetic mutations preventing primer binding, novel pathogens, 
organisms which are not culturable) can be captured by WGS; the identification of a Swedish 
variant of Chlamydia trachomatis which was not detected using conventional methods is an 
illustrative example (Unemo M, 2010). The source of a cholera outbreak in Haiti 2010 was 
identified as peacekeeping forces from Nepal using a WGS approach to confirm and clarify the 
results of a PFGE based investigation (Chin et al., 2011; Oslen R. J., 2012). Recently, single 
nucleotide polymorphism (SNP) analysis of sequences of Yersinia pestis isolates from around 
the world allowed investigators to conclude that this organism evolved from a common ancestor 
in China and radiated globally with explorers and merchants (Morelli et al., 2010).  
Next-generation sequencing is a rapidly developing technique in molecular epidemiology 
facilitating an improved understanding of the source, transmission route, and even mechanisms 
of disease pathogenesis in given population (Lynch et al., 2016). As a surveillance tool, Whole 
genome sequencing has some advantages over other techniques including unparalleled resolving 
power, less bias towards specific regions of the genome, generation of objective and portable 
data (compared to bands) and that it is increasingly technically easy to do and not terribly 
laborious. SNPs in the core genome can be used as a typing tool, and have shown promise in 
forecasting new or re-emerging bacterial strains (Gordon et al., 2014; Kwong and McCallum, 
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2015; Pumina et al., 2015; Zhao et al., 2016). Altogether, WGS facilitate origin of resistance, 
virulence progression and spreading of bacterial lineages in a population, the most influential 
tool in current molecular epidemiology (Price et al., 2013).  
As a molecular epidemiological tool, WGS is now considered the gold standard for identifying 
and monitoring the evolution of multi drug resistant organisms (Pumina et al., 2015). Beyond the 
ability to identify resistant genes, WGS allows the user to identify antimicrobial resistance gene 
complexes, the location of resistance genes in the genome or on mobile genetic elements such as 
a plasmid, genome cassettes, integrons, IS elements and transposons (Gillings, 2014). That 
information may assist understanding resistance gene transfer or horizontal gene transfer of 
resistant determinants in the bacterial population (de Vries et al., 2016).  
Further characterization of mobile genetic elements such as plasmids facilitates understanding 
the source of resistance and relationship among resistance determinants. As an example, clusters 
of infections with organisms containing a novel plasmid which carries blaNDM was identified in 
E. coli and Klebsiella pneumoniae isolated from multiple locations including the community and 
healthcare settings hospitals; such outbreaks are not analyzable using traditional molecular 
epidemiological tools which are limited to a single bacterial species (Khong et al., 2016).  
WGS is currently used in outbreak investigation of clinical disease including spreading and 
transmission of pathogens in hospitals (Popovich and Snitkin, 2017).  In addition, resistance gene 
complexes such as genome cassettes (such as Staphylococcus chromosome cassettes), introns, 
transposons and mobile genetic element can be identified when sequencing the genome (de Vries 
et al., 2016).   
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Table 1.3: Summary of molecular techniques which are commonly used in Staphylococci for 
epidemiological characterization 
Molecular technique Band / 
sequence  
Resolution 
power 
Database 
Random amplification polymorphism 
(RAPD-PCR) 
band high -  
Amplified fragment length polymorphism 
(AFLP) 
band high -  
Pulse field gel electrophoresis (PFGE) band high www.cdc.gov/pulsenet 
www.harmony-microbe.net 
Multilocus variable number tandem 
repeat (MLVA) 
band high www.mlva.net  
Staphylococcus protein A (spa typing) sequence high www.spaserver.ridom.de 
 
Staphylococcus cassette chromosome 
(SCCmec typing) 
sequence low - 
Direct tandem repeat unit (dru typing) sequence low dru.typing.org 
Multilocus sequence typing (MLST) sequence low pubmlst.org 
Whole genome sequencing (WGS) sequence highest - 
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OBJECTIVES 
 
1. To describe the antimicrobial susceptibility of S. pseudintermedius colonizing healthy dogs by 
conducting a surveillance study. 
2. To compare the antimicrobial susceptibility and relatedness of S. pseudintermedius isolated 
from canine urinary and dermatological infections. 
3. To determine the disease incidence, antimicrobial resistance profiles, and sequence types of 
strains of S. pseudintermedius causing human infections in a large Canadian health region. 
4. To compare the susceptibility of S. pseudintermedius to tetracycline, doxycycline, and 
minocycline and to describe the mechanisms of tetracycline resistance. 
 
  
44 
 
2 ANTIMICROBIAL SUSCEPTIBILITY OF Staphylococcus 
pseudintermedius COLONIZING HEALTHY DOGS IN 
SASKATOON, CANADA 
 
 
Copyright 
This article has been reprinted with permission from the Canadian Veterinary Journal. 
Citation 
Priyantha MAR, Gaunt MC, Rubin JE.2016. Antimicrobial susceptibility of Staphylococcus 
pseudintermedius colonizing healthy dogs in Saskatoon, Canada. Canadian Veterinary Journal. 
2016; 57(0).65-69. 
Author Contributions 
Conceived and designed experiment: MARP MCG JER. Performed the experiment: MARP. 
Analyses the Data: MARP JER. Wrote the paper: MARP JER. 
  
45 
 
2.1 Abstract 
This study reports antimicrobial susceptibility of Staphylococcus pseudintermedius carried 
healthy dogs in Saskatoon and describes changes in antimicrobial resistance since a 2008 study. 
One hundred healthy dogs presenting to the wellness services at the Western College of 
Veterinary medicine were screened for S. pseudintermedius by culturing rectal and pharyngeal 
swabs. Staphylococcus pseudintermedius was identified biochemically and antimicrobial 
minimum concentration was determined by broth microdilution. Methicillin resistance was 
confirmed by polymerase chain reaction (PCR) and sequencing of mecA gene. Of 221 S. 
pseudintermedius isolates from 78 dogs, 7 were methicillin resistant. No resistance to the 
fluoroquinolones, nitrofurantoin, tigecycline, vancomycin, quinupristin-dalfopristin, linezolid or 
daptomycin was identified. Of the 78 positive dogs, isolates resistant to penicillin were found in 
78%, ampicillin 61%, and tetracycline 26% while resistance to oxacillin, erythromycin, 
clindamycin, trimethoprim + sulfamethoxazole, chloramphenicol, and gentamicin was found in 
<10% of dogs. Compared to the 2008 study, the frequency of resistance to all drugs increased, 
and the frequency of colonization with pan-susceptible isolates decreased from 46% to 30%.  
 
2.2 Introduction 
Staphylococcus pseudintermedius (recognized as distinct from S. intermedius in 2005) is a 
Gram-positive bacterium which colonizes the skin and mucosal surfaces of up to 90% of healthy 
dogs (Bannoehr and Guardabassi, 2012; Devriese et al., 2005; Rubin and Chirino-Trejo, 2011). 
Clinically, S. pseudintermedius is the most common cause of pyoderma and otitis externa, the 
second most common cause of urinary tract infections and is frequently implicated in nosocomial 
infections in dogs (Ball et al., 2008; van Duijkeren et al., 2011b). The ubiquity of canine S. 
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pseudintermedius infections in the community and the frequency of empiric treatment by 
veterinarians highlights the importance of antimicrobial resistance surveillance to inform 
evidence-based empiric therapeutic selection. 
The emergence of antimicrobial resistance is a great challenge to antimicrobial therapy for 
animals and humans. The propensity of staphylococci to adapt to the selection pressure of 
antimicrobial use has been recognized since the first description of penicillin-resistant S. aureus 
in the 1940s (Barber, 1947). Resistance to penicillin among staphylococci, including companion 
animal S. pseudintermedius isolates, is most commonly due to the production of staphylococcal 
β-lactamase, conferred by the blaZ gene (Fuda et al., 2005; Malik et al., 2007). Staphylococcus 
pseudintermedius has historically remained remarkably susceptible to antimicrobials, but since 
2006 there has been a dramatic worldwide increase in the frequency of methicillin resistance 
(Moodley et al., 2014; van Duijkeren et al., 2011b). Methicillin resistance, which is rapidly 
emerging among S. pseudintermedius in dogs and common among S. aureus in human is a 
serious threat to the efficacy of the most frequently used antibiotics, the β-lactams (Perreten et 
al., 2010; Prescott et al., 2002; Weese and van Duijkeren, 2010). Methicillin resistance conferred 
by the mecA and mecC genes results in the production of altered cell wall proteins with a low 
affinity for β-lactam drugs; leading to resistance to all β-lactam antimicrobials currently licensed 
for use in veterinary medicine including the penicillin, cephalosporins, and carbapenems (Becker 
et al., 2014). Because methicillin resistance is not the product of β-lactamase production, the 
addition of β-lactamase inhibitors such as clavulanic acid does not restore susceptibility. 
Furthermore, methicillin resistance in S. pseudintermedius is often associated with multidrug 
resistance, further limiting the treatment options available to veterinarians (Moodley et al., 2014; 
van Duijkeren et al., 2011a). 
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In the late 2000's there was an explosive increase in the incidence of MRSP associated with two 
lineages of S. pseudintermedius, sequence type (ST) 71 in Europe and ST68 in North America 
(Bardiau et al., 2013; Perreten et al., 2010). Among healthy dogs in North America and Europe 
0-4.5% have been found to carry MRSP, while up to 66% of clinical S. pseudintermedius isolates 
have been reported to be methicillin resistant (Gingrich et al., 2011; Griffeth et al., 2008; 
Hanselman et al., 2007; Hanselman et al., 2009; Kawakami et al., 2010; van Duijkeren et al., 
2011a). In Saskatoon, S. pseudintermedius carried by healthy dogs and those causing infections 
have historically been remarkably susceptible; a 2008 study failed to identify any animals 
carrying methicillin resistant S. pseudintermedius (MRSP) (Ball et al., 2008; Rubin and Chirino-
Trejo, 2011). Since 2009, reports of canine infections with MRSP in Saskatoon including urinary 
tract infections and necrotizing fasciitis suggest the emergence of resistance in this region 
(Mayer and Rubin, 2012; Rubin and Chirino-Trejo, 2011). The objective of this study was to 
determine the antimicrobial susceptibility profiles of S. pseudintermedius colonizing healthy 
dogs in Saskatoon, and identify changes in the frequency of resistance since the 2008 
investigation.  
 
2.3 Material and Methods 
2.3.1 Sample Collection 
Between June and September 2014, 100 clinically healthy dogs presenting to the wellness 
service of the Veterinary Medical Centre at the Western College of Veterinary Medicine were 
included (Table 2.1). Pharyngeal and rectal samples were collected using sterile swabs with 
Stuart transport media (Becton Dickinson and Company, Sparks, MD) as previously described 
(Rubin and Chirino-Trejo, 2011). Pharyngeal samples were collected by gently rolling a sterile 
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swab across the pharynx for 1-3 s, and rectal swabs were collected by gently inserting a second 
swab 3cm into the dog's rectum and rotating for 1-3 s. All samples were processed within 4 
hours of collection. This study was approved by the University of Saskatchewan animal research 
ethics board (protocol #20130135). 
 
2.3.2 Culture and Susceptibility Testing 
All swabs were directly plated on “CHROMagar” Staph aureus (CHROMagar, Paris, France), 
and Mueller-Hinton agar + 4µg/mL oxacillin. Plates were then incubated overnight at 35⁰C and 
up to 5 S. pseudintermedius-like colonies (mauve color) were sub-cultured to Columbia agar 
with 5% sheep blood (Becton, Dickinson). Isolates were identified based on colony morphology 
(small, creamy grey to white, round colonies with a smooth margin and double zone of 
hemolysis on blood agar) and biochemically using the catalase and tube coagulase tests using 
rabbit plasma, the production of acetoin and hyaluronidase and the fermentation of mannitol, 
maltose and trehalose (Rubin and Chirino-Trejo, 2011; Winn et al., 2006). Since the carriage of 
genetically diverse S. pseudintermedius strains by individual dogs has been recognized, 3 isolates 
per animal were saved for future testing to increase the likelihood of detecting resistant 
organisms (Paul et al., 2012). Bacteria were stored at -80⁰C in trypticase soy broth + 15% 
glycerol. For dogs carrying S. pseudintermedius at both sites, 2 pharyngeal and 1 rectal isolate 
were saved. 
Antimicrobial minimum inhibitory concentrations were determined by broth microdilution using 
the GAPLL1F Sensititre panel (Thermo Fisher Scientific, Oakwood Village, Ohio, USA). Tests 
were conducted according to the Clinical and Laboratory Standards Institute (CLSI) and 
manufacturer's guidelines (CLSI, 2012a). A panel of drugs including: penicillin (PEN), 
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ampicillin (AMP), oxacillin (OXA) (with 2% NaCl), erythromycin (ERY), clindamycin (CLI), 
tetracycline (TET), tigecycline (TGC), trimethoprim + sulfamethoxazole (SXT), ciprofloxacin 
(CIP), levofloxacin (LEV), moxifloxacin (MOX), gentamicin (GEN), chloramphenicol (CHL), 
rifampin (RIF), nitrofurantoin (NIT), vancomycin (VAN), linezolid (LZD), daptomycin (DAP) 
and quinupristin + dalfopristin (QDA) was used. For quality control, S. aureus ACTCC 29213 
and Enterococcus faecalis ACTCC 29212 were used (CLSI, 2013). Antimicrobial MICs were 
categorized as susceptible or resistant using CLSI breakpoints for all drugs except tigecycline 
and daptomycin for which the EUCAST interpretive criteria were used (CLSI, 2013, 2014; 
EUCAST, 2014). Isolates were considered to be MRSP when resistant to oxacillin (MIC ≥ 
0.5µg/ml); genotypic resistance was confirmed by PCR and sequencing of the mecA and mecC 
genes using previously described primers (Stegger et al., 2012). Isolates resistant to 
erythromycin and susceptible to clindamycin were tested for inducible clindamycin resistance 
using the D-test as described by the CLSI (CLSI, 2014). 
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Table 2.1: Characteristics of sampled dog (n = 100) 
Age 2.5 months - 12 years (median = 3 years) 
Gender* 
   Intact male 
   Neutered male 
   Intact female 
   Neutered female 
 
18 
33 
14 
32 
 
History of antimicrobial use, past 6 months 
   Yes 
   No 
 
9 
91 
 
* Information on gender was not recorded for 1 dog. 
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2.4 Results 
Of the 100 dogs tested, S. pseudintermedius was isolated from 78. A total of 221 isolates were 
collected, including single isolates from 5 dogs, 2 isolates from 3 dogs, and 3 isolates from 70 
dogs. For dogs in which <3 isolates were initially identified, all isolates were saved. No S. 
pseudintermedius was isolated from Mueller-Hinton agar with 4μg/ml oxacillin, all isolates were 
recovered from CHROMagar Staph aureus. Antimicrobial susceptibility testing revealed 
phenotypic diversity among multiple isolates from individual dogs. Of the 78 positive animals, 
isolates with varying susceptibility profiles were grown from 30, while phenotypically 
homogeneous isolates were grown from 48. Consequently, the frequency of resistance among the 
overall isolate collection was lower than the percentage of animals carrying isolates expressing 
any particular resistance phenotype; for example, if 1 of 3 isolates carried by a dog was resistant 
to tetracycline, that dog is considered to carry tetracycline resistant isolates (Table 2.2). No 
resistance to ciprofloxacin, levofloxacin, moxifloxacin, nitrofurantoin, rifampin, tigecycline, 
vancomycin, quinupristin + dalfopristin, linezolid or daptomycin was identified. The most 
common resistance profile was penicillin + ampicillin resistance (n=70, 31.7%) followed by pan-
susceptibility (n=67, 30.3%) (Table 2.3). Methicillin resistant isolates (n=8) were identified in 7 
(9%) of S. pseudintermedius carrying dogs. Resistance to trimethoprim + sulfamethoxazole, 
chloramphenicol and gentamicin was less common (Table 2.3). All oxacillin resistant isolates 
possessed the mecA gene while mecC was not identified. None of the 5 erythromycin resistants, 
clindamycin-susceptible isolates were inducibly clindamycin resistant. 
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Fifteen multidrug-resistant isolates (MDR; resistance to 3 or more drugs classes) were identified, 
all were methicillin susceptible S. pseudintermedius (MSSP) (Table 2.3). Notably, one isolate 
was resistant to PEN, AMP, ERY, CLI, CHL and GEN.
 
 
5
3
 
Table 2.2: MIC distribution of isolates and the percentage of animals colonized with resistant isolates in 2008 and 2014 
Drug 
(µg/ml) 
0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 % 
Resistant 
Isolates 
2014 
(n=221) 
% 
Animals 
2014 
(n=78) 
% 
Animals 
2008 
(n=153) 
PEN  75 6 8 15 12 6 11 42 46    63.3 73.0 39.9 
AMP   82 32 26 37 26 11 3 4    48.4 61.5 9.8 
OXA    213 2 1   5     3.6 9.0 0 
ERY    134 73 3   11     5.0 9.0 3.3 
CLI     214 1  6      2.7 5.1 2.6 
TET       174 1   46   20.8 25.6 23.5 
TGC  70 142 9          0 0 0 
SXT     210 3  1 7     3.6 3.8 0 
CIP      221        0 0 0 
LEV    214 4 1 2       0 0 0 
MOX    221          0 0 0 
GEN       218 1 1  1   0.5 1.3 0 
CHL        16 175 28 2   0.9 2.6 0 
NIT           221   0 0 0 
RIF     220 1        0 0 0 
VAN    3 204 14        0 0 0 
LZD      138 81 2      0 0 0 
DAP     221         0 0 0 
QDA     219 2        0 0 0 
 
Antimicrobial minimum inhibitory concentration (MIC) distribution for Staphylococcus pseudintermedius isolates (n=221) for 
penicillin (PEN), ampicillin (AMP), oxacillin (OXA) (with 2% NaCl), erythromycin (ERY), clindamycin (CLI), tetracycline (TET), 
tigecycline (TGC), trimethoprim + sulfamethoxazole (SXT), ciprofloxacin (CIP), levofloxacin (LEV), moxifloxacin (MOX), 
gentamicin (GEN), chloramphenicol (CHL), rifampin (RIF), nitrofurantoin (NIT), vancomycin (VAN), linezolid (LZD), daptomycin 
(DAP) and quinupristin + dalfopristin (QDA).Cells corresponding to concentrations tested are outlined in black while the resistance 
breakpoint is shaded. The number of isolates inhibited at each concentration is noted in each cell.
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Table 2.3: Summary of resistance profiles of S. pseudintermedius isolates (n=221) 
Resistance profile Number of isolates 
Pan-susceptible 67 
PEN + AMP 70 
PEN 27 
TET 13 
PEN + AMP + TET 13 
PEN + AMP + OXA 6 
PEN + AMP + SXT + TET 6 
PEN + TET 4 
PEN + AMP + TET + ERY + CLI 4 
PEN + AMP + TET + ERY 3 
PEN + AMP + SXT 2 
PEN + AMP + OXA + TET 1 
PEN + AMP + OXA + ERY 1 
TET + ERY 1 
PEN + ERY + CLI 1 
PEN + AMP + TET + CHL 1 
PEN + AMP + ERY + CLI + CHL + GEN 1 
 
Resistance profiles of S. pseudintermedius isolates (left column), and a number of isolates with 
each profile (right column). Penicillin (PEN), ampicillin (AMP), oxacillin (OXA) (with 2% 
NaCl), erythromycin (ERY), clindamycin (CLI), tetracycline (TET), trimethoprim + 
sulfamethoxazole (SXT), gentamicin (GEN), chloramphenicol (CHL). 
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2.5 Discussion 
Compared to the previous resistance surveillance study targeting S. pseudintermedius from 
healthy dogs presenting to the wellness service at our institution in Saskatoon in 2008, a higher 
frequency of resistance to specific antimicrobials, and resistance to more drugs including MRSP 
was identified. Furthermore, only 30% of the dogs carried pan-susceptible isolates compared to 
46% in 2008 (Rubin and Chirino-Trejo, 2011). Differences in sample collection between the 
present investigation and that done in 2008 (the inclusion of a single isolate per dog in 2008 
versus 3 presently, and the inclusion of nasal swabs in the 2008 investigation) preclude statistical 
comparisons between studies. However, the higher frequency of resistance including MRSP in 
2014 is consistent with local clinical observations suggesting the emergence of resistance and 
with global MRSP trends. The frequency of carriage of healthy dogs with MRSP (7%) was 
higher than previously described elsewhere in North America or Europe (≤4.5%) perhaps 
reflecting the continued emergence of MRSP following previous studies (Hanselman et al., 2009; 
van Duijkeren et al., 2011a). This frequency was lower than that reported in Asia, where up to 
45% colonization has been reported in Thailand, Japan and Hong Kong (Chanchaithong et al., 
2014; Epstein et al., 2009; Sasaki et al., 2007a). The inclusion of Mueller-Hinton agar with 
4μg/ml oxacillin did not improve our ability to recover MRSP despite the identification of 5 
isolates with oxacillin MICs of >4μg/ml. 
 
Risk factors for dogs to be infected with or carry MRSP have not been adequately characterized. 
There is conflicting evidence describing an association between infection with MRSP versus 
MSSP and previous antimicrobial administration (Lehner et al., 2014; Weese et al., 2012). 
Hospitalization and surgical procedures have also been positively associated with MRSP 
56 
 
colonization (Nienhoff et al., 2011; Weese et al., 2012). In the present investigation, none of the 
7 MRSP positive animals were treated with antimicrobials in the previous 6 months, and all were 
clinically healthy suggesting community acquisition of the MRSP. Further study is clearly 
required to define risk factors associated with MRSP in dogs. 
 
A total of 15 (6.8%) of isolates from 7 (9.0% of colonized dogs) were MDR, higher than in 2008 
where only 1 dog carried MDR S. pseudintermedius (Rubin and Chirino-Trejo, 2011). In contrast 
to the literature, MDR was more frequently identified among MSSP than MRSP (Detwiler et al., 
2013). The most common resistance profile among MRSP, including 6 of 8 isolates, was simply 
β-lactam resistance. MDR among MRSP is a serious threat to the ability of veterinarians to treat 
their patients. In 2009, a community associated urinary tract infection caused by MRSP resistant 
to the β-lactams, macrolides, fluoroquinolones, aminoglycosides, trimethoprim-
sulfamethoxazole, chloramphenicol, and rifampin was reported in an otherwise healthy, neutered 
male Pug dog (Rubin and Gaunt, 2011a). Elsewhere, MRSP resistant to all antimicrobials 
licensed for use in companion animals have been described, highlighting the critical role of 
culture and susceptibility testing to guide therapy (Detwiler et al., 2013; Perreten et al., 2010; 
van Duijkeren et al., 2011a). Differences in clinical outcome for human patients infected with 
methicillin resistant versus susceptible staphylococci have not been observed, although the 
typically superficial nature of staphylococcal infections (pyoderma and otitis) may mask 
differences which have been seen in invasive MRSA vs. MSSA infections in people (Ott et al., 
2010; Weese et al., 2012). More studies are needed to define risk factors associated with MRSP 
infection so that appropriate empiric treatments can be applied pending laboratory guided 
therapy. 
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Although ill-defined, antimicrobial resistant S. pseudintermedius is also a public health risk; 
human infections have been reported (Talan et al., 1989a). Because S. pseudintermedius is not 
part of the normal microbiota of humans, the carriage has been reported to be sporadic, 
colonization or infection with this organism is likely zoonotic (Paul, 2015; Paul et al., 2011). 
Presumptive transmission of S. pseudintermedius from dogs to humans working closely with 
them (veterinary staff) and pet owners have been reported; 3.9% - 13% of such people have been 
found to carry this organism (Chanchaithong et al., 2014; Paul et al., 2011; Walther et al., 2012). 
The frequency of human S. pseudintermedius infections may be under-appreciated due to its 
morphological and biochemical similarity to S. aureus leading to misidentification in diagnostic 
labs. The introduction of highly discriminatory identification methods such as MALDI-TOF MS 
which readily differentiates S. pseudintermedius and the closely related S. intermedius and 
S.delphini from S. aureus is helping to identify this previously under-recognized zoonosis (Silva 
et al., 2015). 
 
Antimicrobial resistance appears to be emerging among S. pseudintermedius colonizing healthy 
dogs in Saskatoon, Canada. Although we presume that infections with MRSP are encountered 
with increasing frequency in our region, these data are not available. Culture and susceptibility 
testing should be encouraged to aid in the identification of MRSP in veterinary patients and to 
guide antimicrobial therapy. Practitioners should be aware of methicillin resistance when 
prescribing empiric antimicrobial therapy. Methicillin resistance should be suspected when 
empiric β-lactam therapy fails to cure S. pseudintermedius infections or for isolates demonstrated 
to be resistant to potentiated penicillins such as amoxicillin + clavulanic acid. Further studies to 
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describe the susceptibility of clinical isolates in this region would be complementary to this 
investigation. 
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2.7 Transition Statement 
The first study was designed to identify S. pseudintermedius colonizing healthy dogs and to 
evaluate the trend of antimicrobial resistance compared to the baseline study which was done in 
2008. The results suggested that the frequency of resistance to penicillin and tetracycline has 
increased in Saskatoon, and that healthy dogs may now be colonized with MRSP, which was not 
seen in the baseline study. MRSP is often multidrug resistant and therapeutic options are limited 
for veterinarians. Dermatological and urinary tract infections are commonly caused by S. 
pseudintermedius. Although strain specific infections are seen in some bacterial species (such as 
uropathogenic E. coli), this has not been investigated in S. pseudintermedius. Therefore, we were 
interested to determine if dermatological and urinary tract infections are caused by unique strain 
type of S. pseudintermedius and whether differences in phenotypic antimicrobial susceptibility 
between them could be identified. We also investigated the emergence of antimicrobial 
resistance including MRSP in clinical isolates from S. pseudintermedius in dogs.  
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3.1 Abstract 
Staphylococcus pseudintermedius is an important pathogen in dogs; it is the most common cause 
of skin infections and the second most common cause of urinary tract infections. The ostensibly 
different environments of the urinary bladder and skin led us to hypothesize that isolates would 
cluster genetically by the site of infection (uro- and dermato- pathotypes). A collection of clinical 
urinary (n=50) and dermatological (n=51) isolates from unique patients were collected from a 
regional diagnostic laboratory. The antimicrobial susceptibility of isolates was determined by 
broth micro-dilution, and the relatedness of isolates was compared by pulse-field gel-
electrophoresis and multi-locus sequence typing. DNA fingerprinting revealed that the isolates 
were genetically heterogeneous; 6 of 7 clusters identified by pulsed-field contained isolates from 
both infection types. Isolates from dermatological infections were significantly more likely to be 
resistant to erythromycin, clindamycin, and chloramphenicol than urinary isolates. Although not 
significant, methicillin resistance was numerically more common among dermatological than 
urinary isolates. These results indicate that opportunism is a more important factor than strain 
specific tissue tropism to the site of S. pseudintermedius infection in dogs. Although 
confirmatory studies are required, we propose that differences in the susceptibility of isolates 
from dermatological and urinary infections may be related to the clinical course of these diseases 
and the recurrent therapy. 
 
3.2 Introduction  
Staphylococcus pseudintermedius colonizes up to 90% of healthy dogs and is the most common 
cause of skin infections and the second most common cause of urinary tract infections in dogs 
(Rubin and Chirino-Trejo, 2011). Although there are many studies describing dermatological 
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isolates of S. pseudintermedius, there are few investigations into those from urinary infections; 
the published literature is limited to case reports and a description of the susceptibility of 
diagnostic isolates (Penna et al., 2010; Rubin and Gaunt, 2011b; Windahl et al., 2012). The skin 
and urinary tract are ostensibly dramatically different environments imparting unique obstacles 
to bacterial growth. While several virulence factors associated with dermato-pathogenesis 
including exfoliative toxin and fibronectin binding proteins have been demonstrated, the 
requisite virulence factors for S. pseudintermedius to cause urinary infections have not been 
identified (Iyori et al., 2011; Iyori et al., 2010; Pietrocola et al., 2015; Wladyka et al., 2015). It is 
unknown if isolates causing urinary and dermatological infections have unique virulence factor 
profiles, or if there are differentiable uro- or dermato-pathogenic strains. In S. aureus the 
association between strain and virulence genes is well recognized. Panton-Valentine Leucocidin 
(PVL) is associated with USA300, a community-acquired MRSA strain, which is recognized as a 
cause of skin and soft tissue infections and necrotizing pneumonia (Otto, 2010).  
The emergence of antimicrobial resistance, including methicillin resistance, in S. 
pseudintermedius, is increasingly challenging the treatment of infections. Methicillin resistance 
conferred by the mecA gene results in resistance to the entire β-lactam class of antimicrobials 
which are the most commonly used drugs in companion animals (Prescott et al., 2002). Since 
2006, there has been a dramatic worldwide increase in the frequency of MRSP among clinical 
canine infections (Moodley et al., 2014; van Duijkeren et al., 2011a). The literature has been 
heavily biased towards dermatological isolates where the emergence of MRSP in canine 
dermatological infection is well documented (Kadlec and Schwarz, 2012; Kadlec et al., 2011; 
Vincze et al., 2010). Although there are fewer reports, multi drug resistant MRSP from UTIs 
have also been described (Penna et al., 2010). This emergence has been associated with specific 
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clones, ST68 in North America and ST71 in Europe (Perreten et al., 2010). In our region, the 
frequency of MRSP colonization of healthy dogs increased from 0% to 9% between 
investigations conducted in 2008 and 2014 respectively (Priyantha et al., 2016). Anecdotal 
observations from companion animal clinicians suggest that resistance is more problematic 
among dermatological than urinary S. pseudintermedius isolates.  
The objectives of this study were therefore to compare the antimicrobial susceptibility profiles 
and relatedness of S. pseudintermedius isolates from clinical urinary and dermatological 
submissions to a regional veterinary diagnostic laboratory. We hypothesized that resolvable uro- 
and dermato-pathotypes would be identifiable and that antimicrobial resistance would be more 
common among dermatological than urinary isolates.  
 
3.3 Material and methods  
Staphylococcus pseudintermedius isolates were collected from clinical submissions to Prairie 
Diagnostic Services, a regional veterinary laboratory located in Saskatoon, Canada. A total of 
101 sequentially isolated S. pseudintermedius from dermatological (n=51) and urinary (n=50) 
submissions were gathered over a two-year period beginning in November 2013. Laboratory 
records were reviewed to ensure that duplicate isolates from the same patient were excluded 
from the study. Bacteria were stored at -800C in trypticase soy broth with 15% glycerol prior to 
analysis. 
Antimicrobial minimum inhibitory concentrations were determined using the Sensititre system 
(GPALL1F plate format) including penicillin (PEN), ampicillin (AMP), oxacillin with 2% NaCl 
(OXA), chloramphenicol (CHL), erythromycin (ERY), clindamycin (CLI), gentamicin (GEN), 
tetracycline (TET), tigecycline (TGC), sulfamethoxazole + trimethoprim (SXT), levofloxacin 
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(LEV), ciprofloxacin (CIP), moxifloxacin (MOX), rifampicin (RIF), nitrofurantoin (NIT), 
vancomycin (VAN), daptomycin (DAP), linezolid (LZD) and quinupristin + dalfopristin (QDA). 
Antimicrobial susceptibility tests were conducted and interpreted according to the CLSI 
guidelines (2013; 2014). For daptomycin and tigecycline, EUCAST resistance breakpoints for S. 
aureus were used (EUCAST, 2014). S. aureus ACTCC 29212 and E. feacalis ACTCC 29212 
were included for quality control. All Isolates were screened for mecA using previously 
published primers (Stegger et al., 2012).  
The relatedness of isolates was determined using pulsed-field gel electrophoresis using a 
previously published protocol (Mulvey et al., 2001). Salmonella Branderup was used as a 
molecular weight ladder as described by PulseNet (http://www.cdc.gov/pulsenet). A CHEF DR-
III apparatus (Bio-Rad) was used for electrophoresis using switch times of 5.3 to 34.9 for 18 h at 
6.0 V/cm gel images were digitized and analyzed with GelCompare (Applied Maths, Austin, 
TX). Banding patterns were compared using the Dice algorithm and dendrograms were 
constructed using UPGMA. According to the Tenover criteria, isolates were considered to be 
related if they were at least 80% similar and Clusters were defined as groups 3 or more related 
isolates (Tenover et al., 1995). Methicillin resistant isolates were further characterized by MLST 
to provide an additional objective, a sequence based measure of relatedness (Solyman et al., 
2013).  
Differences in the frequency of categorical antimicrobial susceptibility (susceptible vs. resistant) 
and multi-drug resistance (≥ 3 classes) between dermatological and urinary isolate collections 
were compared using Fisher's exact test. Statistical analysis was done using the freely available 
online calculator GraphPad (http://graphpad.com/quickcalcs/contingency2/). A p-value of ≤0.05 
was considered statistically significant. 
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3.4 Results 
Overall, isolates were resistant to between 0 and 6 drug classes (median 1), with the most 
common phenotype identified being pan-susceptibility (Table 3.1). No resistance to 
nitrofurantoin, rifampin, vancomycin, linezolid, daptomycin, tigecycline or quinupristin + 
dalfopristin was identified. Although numerically more urinary than dermatological isolates was 
pan-susceptible (18 vs. 16 respectively), this difference was not significant (p = 0.67). The 
opposite trend was seen for multidrug resistance which was observed in numerically more 
dermatological than urinary isolates (7 and 2 respectively), this difference approached 
significance (p = 0.09). With the exception of penicillin and trimethoprim + sulfamethoxazole, 
resistance to all other drugs was more frequently identified in dermatological than urinary 
isolates (Table 3.2). For erythromycin, clindamycin, and chloramphenicol these differences were 
significant while for oxacillin resistance (MRSP) this difference approached significance. All 
oxacillin resistant isolates possessed mecA, while this gene was not identified among any 
oxacillin susceptible isolates. Finally, a greater diversity of resistance phenotypes was found 
among dermatological than urinary isolates (Table 3.1).  
Of the 101 isolates tested by PFGE, one was indigestible by Sma1 and was excluded from 
subsequent analyses. Mutually exclusive clusters of urinary and dermatological isolates were not 
identified. Isolates were generally unrelated, 7 clusters including 25 isolates (13 dermatological 
and 12 urinaries) were identified; 6 clusters contained isolated from both types of infections. The 
eight methicillin resistant isolates didn't cluster together by PFGE, this was corroborated by 
MLST which revealed that eight unique sequence types (Table 3.3). While isolates SP36 and 
SP56 only differ at a single locus and isolates SP56 and SP60 differ at two loci, all other isolates 
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were no more similar than triple locus variants of each other. Importantly, the European 
pandemic clone ST71 was identified in Saskatoon, Canada. 
67 
 
Table 3.1: MIC distribution of S. pseudintermedius isolated from canine dermatological (n=51) 
and urinary tract (n=50) infections 
Drug 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 R
% 
Site P value 
PEN  22  1 1   3 3 21   56.8 Derm 0.8 
 20  2 2 2 6 1 5 12   60.0 UTI 
AMP   22 5 4 5 3 3  9   47.0 Derm 1.00 
  20 7 8 6 3 3 1 2   43.1 UTI 
OXA    43  1 1  6    15.7 Derm 0.06 
   49     1    1.9 UTI 
ERY    39 4    9    17.6 Derm 0.02 
   43 6    1    1.9 UTI 
CLI     42   9     17.6 Derm 0.02 
    49   1     1.9 UTI 
TET       34 1 4  12  23.5 Derm 0.81 
      36  4  10  20.0 UTI 
SXT     45  2  4    7.8 Derm 1.00 
    44  2  4    8.0 UTI 
GEN       47 1 2 1 1  3.9 Derm 1.00 
      49   1   1.9 UTI 
CHL       0 14 27 3 7  13.7 Derm 0.01 
      1 20 21 8   0 UTI 
CIP      49  3       5.8 Derm 0.62 
     49   1    1.9 UTI 
LEV    44 2 2   3    5.8 Derm 0.62 
   48  1   1    1.9 UTI 
MOX    48    3     5.8 Derm 0.62 
   49    1     1.9 UTI 
 
PEN: penicillin, AMP: ampicillin, OXA: oxacillin, ERY: erythromycin, CLI: clindamycin, TET: 
tetracycline, SXT: sulfa-trimethoprim, GEN: gentamicin, CHL: chloramphenicol, CIP: 
ciprofloxacin, LEV: levofloxacin, MOX: moxifloxacin, Derm : clinical isolates from 
dermatological infection, UTI: clinical isolates from urinary tract infection. The dark vertical line 
indicates the clinical breakpoint for the given antimicrobial agent. 
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Table 3.2: Antimicrobial susceptibility profiles of S. pseudintermedius isolated from 
dermatological (n=51) and urinary tract (n=50) infections in dogs. 
Susceptibility Profile Dermatological  
Isolates 
Urinary  
Isolates 
Pan susceptible 16 (31.3%) 18(36%) 
PEN 4 (7.8%) 5 (10%) 
TET 4 (7.8%) 2 (4%) 
PEN + AMP 13 (27.4%) 15 (30%) 
PEN +TET 0 1(2%) 
PEN +SXT 0 1 (2%) 
TET + CHL 1 (2%) 0 
ERY + CLI 1 0 
PEN + AMP + TET 0 6 (12%) 
PEN + AMP + SXT 1 (2%) 0  
PEN + AMP + TET + SXT 0 1(2%) 
PEN + TET + ERY + CLI + CHL 1 0 
PEN + AMP + ERY + CLI + TET + CHL 3 (5.9%) 0 
MRSP 1 (2%) 0 
MRSP + TET 1 (2%) 0 
MRSP + SXT 1 (2%) 0 
MRSP + ERY + CLI 1 (2%) 0 
MRSP + CHL + ERY + CLI + GEN + SXT + CIP + LEV + MXF 1 (2%) 1 (2%) 
MRSP + CHL + ERY + CLI + TET + SXT + CIP + LEV + MXF 1 (2%) 0 
MRSP + CHL + ERY + CLI + GEN + TET + CIP + LEV + MXF 1 (2%) 0 
 
Penicillin (PEN), ampicillin (AMP), oxacillin (OXA) (with 2% NaCl), erythromycin (ERY), 
clindamycin (CLI), tetracycline (TET), trimethoprim + sulfamethoxazole (SXT), gentamicin 
(GEN), chloramphenicol (CHL). 
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Table 3.3: Summary of multilocus sequence typing data (MLST) from MRSP isolates found in 
the study. 
Isolate 
ID 
Infection 
Site 
Allelic profile ST 
ack cpn60 fdh pta purA sar tuf 
SP04 Skin 17 2 2 44 46 1 2 644 
SP18 Skin 2 10 2 44 18 1 2 645 
SP36 Urine 3 9 1 2 22 2 1 684 
SP51 Skin 16 13 8 48 11 1 2 669 
SP56 Skin 3 9 1 2 1 2 1 71 
SP60 Skin 2 9 4 2 1 2 1 646 
SP72 Skin 2 8 2 1 11 1 2 292 
SP110 Skin 12 13 2 1 11 2 2 670 
 
  
70 
 
3.5 Discussion  
Staphylococcus pseudintermedius is one of the most common causes of infections in dogs and 
yet we know little about the organism factors contributing to pathogenesis. We hypothesized that 
the unique environment of the skin and urinary bladder would select for different "pathotypes" of 
S. pseudintermedius which we attempted to resolve using DNA fingerprinting techniques. We 
were surprised to find that in our collection, urinary and dermatological isolates did not cluster 
independently by PFGE; these results were corroborated by MLST. These data suggest that 
opportunism is a more important factor than strain specific tissue tropism to the site of S. 
pseudintermedius infection. Interestingly, MLST also revealed that one isolate was ST71, which 
is reportedly a clone more common in Europe (Perreten et al., 2010). A recent report of human S. 
pseudintermedius infections from a neighboring region of Canada also identified 4 of 6 MRSP 
isolates as ST71 while not finding any ST68 (Somayaji et al., 2016). In North America, there is a 
substantial geographic bias against our region in published studies of S. pseudintermedius, but 
our results suggest that ST71 is perhaps less geographically limited than previously thought. 
Significant differences in the frequency of antimicrobial resistance were found between urinary 
and dermatological isolates including a nearly significant association of methicillin resistance 
with dermatological isolates. DNA fingerprinting revealed that these differences are not 
attributed to strain type.  
One possible explanation for this difference is the clinical course of dermatological vs. urinary 
tract infections in dogs and how these syndromes are treated. The appearance and integrity of the 
skin are influenced by systemic factors including nutritional status, hormone levels, perfusion 
and systemic organ function (Outerbridge, 2013). Endocrine diseases offer a particularly pointed 
example of an underlying disease that manifests as a dermatological disease (Outerbridge, 2013). 
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While urinary tract infections may also occur with some endocrinopathies, they are frequently 
subclinical, making them more difficult to identify (Forrester et al., 1999). Dog owners more 
readily identify skin lesions caused by pyoderma and the resulting pruritus, causing them to seek 
treatment.   
While uncomplicated UTIs are relatively straightforward to identify, endocrinopathies are 
challenging to diagnose, possibly resulting in repeated treatment of recurrent pyoderma and 
additional selection pressure for development antimicrobial resistance. Additionally, 
uncomplicated UTI are often successfully cleared with shorter courses of antimicrobial therapy 
compared to pyoderma, particularly deep pyoderma, which may mitigate compliance-related 
treatment failure.  
 
3.6 Conclusion 
We found that S. pseudintermedius causing dermatological and urinary infections do not form 
mutually exclusive genetic clusters suggesting that site of infection is opportunistic rather than 
associated with strain-specific tissue tropism. Furthermore, we argue that differences in 
antimicrobial susceptibility between dermatological and urinary isolates can be explained by 
differences in antimicrobial usage resulting from differences in the clinical course of the disease. 
Further studies are required to understand the pathogenesis of canine S. pseudintermedius 
infections and the factors leading to the development of antimicrobial resistance. 
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3.8 Transition Statement 
Antimicrobial resistance is emerging in S. pseudintermedius isolates from dogs. As common 
house pets, humans and dogs have close contact providing ample opportunity for the 
transmission of organisms. Staphylococcus pseudintermedius is infrequently described as a cause 
of infection in people in the literature. Consequently, many physicians and diagnostic 
laboratories are not aware of S. pseudintermedius. We suspected that S. pseudintermedius has 
been under-recognized as a cause of human infections and is often misdiagnosed as S. aureus. 
We were interested to understand the incidence of S. pseudintermedius in human diagnostic 
submission and to describe the antimicrobial susceptibility of S. pseudintermedius from clinical 
infections and understanding of human clinical infections. Furthermore, we wanted to identify 
existing S. pseudintermedius epidemic clones which causes human infections in our region.  
Additionally, as there are differences in clinical oxacillin resistance breakpoint for S. aureus and 
S. pseudintermedius, we suspect that methicillin resistance may be underreported. Therefore, our 
goal was to identify and characterize S. pseudintermedius from human clinical infection and 
understanding molecular epidemiology in a large Canadian health region.  
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4.1 Abstract 
Staphylococcus pseudintermedius has been recently identified as a novel species within the 
genus Staphylococcus and is commonly associated with infections in dogs. Currently, there are 
few reports of human infections due to this bacterium. The objective of the study was to use a 
population-based approach to describe the characteristics of human Staphylococcus 
pseudintermedius infections in a large Canadian healthcare region. all adult cases aged ≥18 years 
identified at a large regional laboratory from April 1, 2013, to April 1, 2015, who had at least one 
positive culture for Staphylococcus pseudintermedius were retrospectively reviewed. A 
combination of phenotypic methods, mass spectrometry (i.e., MALDI-TOF), and cpn60 
sequencing were used to identify Staphylococcus pseudintermedius. Chart review was 
conducted, and cases were analyzed descriptively.  
Twenty-seven isolates of S. pseudintermedius from 24 human cases were included for analysis. 
58.3% were male with median age of 61 years (IQR 55-70.5). Most patients [22 (92.1%)] had 
confirmed contact with dogs at the time of infection. Staphylococcus pseudintermedius was 
isolated in 18 cases (75.0%) of skin and soft tissue infections (SSTI), and 2 invasive cases 
(8.3%) including a prosthetic joint and bloodstream infection. The other 4 patients were 
colonized (skin – 3; lung – 1). Methicillin resistance was identified in 3 cases with 6 total isolates 
(22.2%); multi-drug resistance was also demonstrated commonly. In Conclusion, Staphylococcus 
pseudintermedius is most commonly associated with SSTIs in humans. Transmission probably 
occurs from a pet dog. Species-level identification of S. pseudintermedius is important due to the 
high prevalence of antibiotic resistance, particularly to methicillin. 
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4.2 Introduction 
Staphylococcus pseudintermedius is a novel coagulase-positive Staphylococcus species 
identified in the last decade (Devriese et al., 2005). Although this organism has been commonly 
associated with skin and soft tissue infections (SSTIs) in dogs, few human cases have been 
described (Chuang et al., 2010; Savini et al., 2013; Stegmann et al., 2010; Van Hoovels et al., 
2006). This bacterium, however, appears to cause a similar infection spectrum as S. aureus in 
humans (Bannoehr and Guardabassi, 2012; Paul et al., 2012). Approximately 90% of healthy 
dogs are colonized with S. pseudintermedius, and frequent sites of isolation include the pharynx, 
rectum, nares, and skin (Rubin and Chirino-Trejo, 2011; van Duijkeren et al., 2011b). As an 
opportunistic pathogen, S. pseudintermedius is the leading cause of pyoderma and otitis externa 
and is also the most commonly isolated pathogen in urinary tract infections (Rubin and Chirino-
Trejo, 2011). Methicillin resistance is rapidly emerging in S. pseudintermedius (Bannoehr and 
Guardabassi, 2012; Beever et al., 2015) with a higher incidence amongst clinical isolates in dogs 
(Beck et al., 2012; Gold et al., 2014), and this may also have important treatment implications in 
human infections (Bannoehr et al., 2009; Kadlec and Schwarz, 2012; van Duijkeren et al., 
2011a). 
The Staphylococcus genus is comprised of 38 species and 17 subspecies of which half are native 
to humans. S. pseudintermedius is a coagulase-positive staphylococcal species and is difficult to 
distinguish from S. aureus on the basis of morphologic characteristics. Although genetic 
sequencing of the cpn60 or sodA genes readily identifies S. pseudintermedius (Sasaki et al., 
2007b), this is currently not a cost-effective modality in clinical practice. However, 
implementation of mass spectrometry instrumentation [i.e. matrix-assisted laser 
desorption/ionization time of flight (MALDI-TOF)] in our regional clinical microbiology 
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laboratory has allowed rapid and accurate identification of clinically relevant bacterial species 
including S. pseudintermedius (Silva et al., 2015). Since the implementation of Vitek MS 
MALDI-TOF, several S. pseudintermedius cases from ambulatory patients have been diagnosed, 
which would have previously been unrecognized or misidentified using phenotypic methods. As 
S. pseudintermedius has been primarily associated with infections in companion animals, 
acquisition of this organism in humans suggests a zoonotic transmission event from dogs. 
With a paucity of literature, little is known regarding the incidence and clinical characteristics of 
S. pseudintermedius infection in humans. It was therefore of interest to perform a population-
based study to describe the epidemiology and clinical and microbiological characteristics of S. 
pseudintermedius infections in our large Canadian healthcare region.  
 
4.3 Material and methods 
4.3.1 Laboratory setting 
Calgary Laboratory Services (CLS) is a large regional diagnostic laboratory that provides 
comprehensive testing services to an urban population of ~1.5 million people. All clinical 
microbiology testing is performed in a single centralized facility, on hospitalized, ambulatory 
and long-term care patients. Clinical samples are promptly transported to CLS following 
collection. Detailed instructions about proper specimen collection requirements are available in 
the CLS Guide to Services found at https://www.calgarylabservices.com/lab-services-
guide/specimen-collection/(CLSGT).  
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4.3.2 Patient and bacterial specimen selection 
A retrospective review of all adult patients aged ≥ 18 years with at least one culture positive for 
S. pseudintermedius was included. Subjects were identified when S. pseudintermedius was 
isolated from clinical specimens submitted to the CLS Microbiology laboratory during the study 
period between April 1, 2013, and April 1, 2015. All clinical specimens analyzed by CLS were 
done as part of the routine clinical care of patients.  Demographic and clinical data including age, 
sex, comorbidities, and details of the nature and treatment of the infection was obtained through 
detailed chart review.  
 
4.3.3 Ethics 
This study was approved by the Conjoint Health Research Ethics Board (CHREB), Alberta 
Health Services and University of Calgary (REB13-0953). Informed consent was obtained from 
each patient case included in the study.  
 
4.3.4 Microbiology Methods 
All S. pseudintermedius isolates grew well on blood agar plates under aerobic incubation at 35oC 
within 24-48 h. The colonies were creamy white and non-haemolytic or demonstrated small 
zones of β-haemolysis. Colony Gram-stain showed small clusters of Gram-positive cocci that 
resembled staphylococci. All isolates were catalase and slide coagulase positive.  They were 
subsequently identified using a commercial mass spectrometry system (Vitek MS®, ACQ 
Software R2 version 1.4.2b, bioMérieux, St.-Laurent, Que.) using Myla Version 3.2.0-4 in 
accordance with the manufacturer’s instructions. Ethanol-formic acid extraction was performed 
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on all isolates using the protocol provided by the manufacturer. A quantity of 1 µL of the 
extracted supernatant was placed on the steel target plate, dried and overlaid with 1 µL of the 
matrix. The target plate was then loaded into the Vitek MS instrument for analysis. 
Molecular identification of the S. pseudintermedius isolates was done by sequencing of the 
cpn60 universal target using previously established methods (Hill et al., 2004). BLAST search 
against the SmartGene-Integrated Database Network System (IDNS) for bacteria indicated the 
most closely related species, and the overall identity score for all isolates was ≥ 99.9% with 0-2 
mismatches (15, 16). Antibiotic susceptibility testing was conducted in accordance with Clinical 
Laboratory Standards Institute (CLSI) guidelines, M100-S24 (2014). Of note, the oxacillin 
resistance breakpoint for  S. pseudintermedius (0.5 μg/ml) is set lower than that of S. aureus (4 
μg/ml) (2015). Antimicrobial susceptibility profiles were initially determined by the automated 
Vitek 2 system (bioMérieux) and confirmed by broth microdilution using the Sensititre system 
(Thermo Fisher Diagnostics (Trek Diagnostics), Ohio, USA). The following drugs were tested 
on all of the isolates: penicillin, ampicillin, oxacillin, erythromycin, clindamycin, 
chloramphenicol, tetracycline, trimethoprim-sulfamethoxazole, gentamicin, ciprofloxacin, 
moxifloxacin, levofloxacin, rifampicin, vancomycin, daptomycin, linezolid, and Synercid 
(quinupristin + dalfopristin). All isolates were screened for the mecA gene by PCR using 
previously published primers, and the identity of amplicons was confirmed by sequencing 
(Stegger et al., 2012). Additionally, S. pseudintermedius isolates were characterized using a 
previously described multi-locus sequence typing method (Solyman et al., 2013). 
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4.3.5 Statistical analysis 
Parametric and non-parametric variables were reported as means with standard deviations (SD) 
and medians with interquartile ranges (IQR) respectively. Patient demographic and clinical data 
were analyzed in a descriptive manner. Prevalence of MRSA in soft tissue and invasive 
infections was compared using X-squared analysis. Annual incidence rates for S. 
pseudintermedius infections were calculated utilizing epidemiologic data from CLS. Sequences 
generated for MLST were concatenated using the online analysis tool found on the PubMLST 
database (www.pubmlst.org). Study outcomes were established prior to data collection. 
Hypotheses were two-sided with α significance of 0.05. Clinical data were analyzed using 
STATA 13.1 software (College Station., Texas). 
 
4.4 Results 
A total of 24 patient cases and 27 isolates were included in the analysis. 58.3% were male with 
median age of 61 years (IQR 55.0 - 70.5 years). Patient characteristics and culture results are 
summarized in Table 4.1 and 4.2. S. pseudintermedius was most commonly associated with skin 
and soft tissue infections (18/24, 75.0%), and patients were primarily managed as outpatients 
(21/24, 87.5%). Diabetes mellitus (29.2%), peripheral vascular disease (20.8%), and 
cardiovascular disease (16.7%) were the most prevalent co-morbidities affecting the cohort. Two 
patients developed invasive S. pseudintermedius infections including a fistula-associated 
bloodstream infection and a monomicrobial prosthetic joint infection. S. pseudintermedius was a 
component of a polymicrobial milieu in the majority of clinical presentations (22/24, 91.7%).   
The other four patients, who had S. pseudintermedius isolated, were considered to be colonized 
and not clinically infected with this organism based on our review. Of the clinical cases where 
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data was available, 95.4% (21/22) of patients had a pet dog during the study period in temporal 
relation to cultures; one patient was bitten by a dog and incurred a soft tissue infection. The 
incidence of bloodstream infection with S. pseudintermedius was 6.95*10E-4% in the study 
period (⸞71900 cultured/year); 30% of these cultures were positive for S. aureus. The incidence 
of true infection with S. pseudintermedius was 20/24 resulting in a rate of 83.3%.  In contrast, the 
rate of blood culture positivity for S. aureus was 0.0055% per year in the 2013-15 periods. 
Similarly, for SSTI or wound infections where cultures were done, the incidence of S. 
pseudintermedius was estimated at 0.05% for the study period (⸞21090 cultures/year); 30% of 
these cultures were positive for S. aureus. 
 
Comprehensive assessment of the 27 S. pseudintermedius isolates was conducted. Most of them 
[23 (85.1%)] were from the skin and soft tissue samples collected most commonly from the 
lower limbs (n = 18). Three of the isolates were associated with invasive infections as previously 
described in the clinical cases (Table 4.1 & Table 4.2). On antimicrobial susceptibility testing, 
seven (26%) of the isolates were pan-susceptible. No inducible clindamycin resistance or 
vancomycin resistance was detected. A total of 6 methicillin-resistant S. pseudintermedius 
(MRSP) isolates (22.2%) corresponding to 3 patients were identified. These isolates were 
implicated in SSTI (4/6) and a prosthetic joint infection (2/6). Of note all MRSP isolates were 
resistant to multiple drug classes; two isolates were identified to be resistant to the β-lactams, 
tetracycline, macrolides, aminoglycosides, sulfonamides and the fluoroquinolones. All MRSP 
were positive for the mecA gene, which was not detected from MSSP isolates. The prevalence of 
MRSP in SSTI compared to invasive infections was similar (p = 0.14). MLST revealed that 16 of 
27 isolates belonged to new sequence types not previously described. Methicillin-resistant 
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isolates belonged to ST71 (n=4) and ST181 (n=2). Within this collection, isolates were generally 
unrelated.  With the exception of the ST71 and ST181 isolates, no isolates were more similar 
than least double locus variants of each other.  
 
 Table 4.1: Demographic and clinical characteristics of patients 
ID AGE & 
SEX 
PROFILE SITE DIAGNOSIS ID – CULTURE TREATMENT  OUTCOME MRSP  
1     63F 
 
Lymphoma, CHF, 
HTN 
Neck SSTI GPB 
S. pseudintermedius 
Cefazolin 2 grams IV q8h 
+ Metronidazole 500 mg 
PO BID * 10 days 
Discharged home No 
2 59M Venous stasis Left leg SSTI Group C Streptococcus, 
Acinetobacter baumanii, 
CoNS 
S. pseudintermedius  
Cephalexin 500 mg PO 
QID * 10 days 
Managed as outpatient No  
3 59M  Umbilicus SSTI CoNS 
S. viridans  
S. pseudintermedius 
Fucidin 2% cream to area 
BID * 10 days 
Managed as outpatient No 
4  53M ESRD (hemodialysis), 
lymphedema, smoker 
Vascular Bacteremia + Fistula 
Wound infection 
S. pseudintermedius (blood) 
S. aureus (from wound) 
Vancomycin IV (at 
dialysis) * 4 weeks 
Managed as outpatient No 
5 34M Dog bite Skin SSTI Pasteurella multocida 
CoNS  
S. pseudintermedius 
Wound sutured 
Ceftriaxone/clindamycin 
IV * 4 days followed by 
amoxicillin-clavulanate 
875 mg PO BID * 7 days 
Non-adherence requiring 
repeat assessment, sutures 
removed 1 week later. No 
change to antibiotics. 
Managed as outpatient 
No 
6 54M DM, CAD, OA, ex-
smoker, thoracic 
surgery; preceding 
wire removal 
Sternum SSTI/abscess CoNS 
S. pseudintermedius 
P. acnes 
 
OR for sternal wire 
removal + cloxacillin 500 
mg PO QID * 7 days 
Discharged home No 
7 75M Ex-smoker Lung Nodule – r/o 
infection 
Oropharyngeal flora 
S. pseudintermedius 
 
Amoxicillin-clavulanate 
875 mg PO BID * 5 weeks 
Managed as outpatient; 
non-infectious etiology 
No 
8 65M GI bleeding Left knee 
(soft tissue) 
SSTI S. pseudintermedius Cephalexin 500 mg PO 
QID * 10 days 
Managed as outpatient No 
9 60F  Left foot R/O infection S. pseudintermedius Expectant management Managed as outpatient; no 
infection diagnosed 
No 
10 61M  Left leg SSTI Enterococcus spp 
S. pseudintermedius 
Doxycycline 100 mg PO 
BID * 10 days 
Managed as outpatient No 
11 67M DM, PVD (stenting), 
smoker 
Right foot 
(1st toe) 
SSTI Staphylococcus lugdensis 
S. pseudintermedius  
Cephalexin 500 mg PO 
QID * 10 days 
Managed as outpatient No 
12 40M  Right foot SSTI, R/O fungal 
infection 
GNEB 
Aerococcus viridans 
S. pseudintermedius 
Fucidin 2% cream daily * 
2 weeks + Terbinafine 250 
mg PO daily * 4 weeks 
Managed as outpatient No 
13 49M DM, prior right foot 
infections (great toe 
fusion history) 
Left foot SSTI S. pseudintermedius Clindamycin 300 mg PO 
QID * 10 days 
Managed as outpatient No 
14 61F  Left foot 
(1st toe) 
R/O infection GNB (failed to grow) 
CoNS 
S. pseudintermedius 
Expectant management  Managed as outpatient, no 
infection diagnosed 
No 
15 82M Afib, DVT, obesity Right foot SSTI S. pseudintermedius 
CoNS 
Amoxicillin 500 mg PO 
TID * 9 days 
Managed as outpatient Yes (3 
isolates) 
16 74F CVA, RA, OP Left foot 
(1st toe) 
SSTI S. aureus 
Group B Streptococcus 
Cephalexin 500 mg PO 
QID * 7 days 
Managed as outpatient No 
8
3
 
 S. pseudintermedius 
17 80F DM, renal transplant, 
OA, R total knee 
arthroplasty 
Right knee 
(prosthesis) 
Prosthetic joint 
infection 
S. pseudintermedius Right knee aspiration +  
Did not tolerate 
vancomycin or linezolid; 
Tigecycline 50 mg IV 
q12h * 3 months 
Repeat admission in 2014 
requiring partial prosthesis 
removal + intravenous 
antibiotics 
Yes (2 
isolates) 
18 74F 
 
ESRD on HD, DM, 
Afib, HTN, PVD with 
bilat leg amputation, 
GIB, chronic pain 
 
Right knee 
stump  
SSTI GNEB 
S. pseudintermedius  
Vancomycin IV * 4 weeks 
+ wound care 
Managed as outpatient No 
19 67F 
 
OA Left leg SSTI S. pseudintermedius Levofloxacin 500mg PO 
daily * 7 days 
Managed as outpatient Yes  
20 56F 
 
OA Right leg SSTI S. pseudintermedius Ceftriaxone 2g IV daily + 
metronidazole 500mg PO 
BID * 3 days followed by 
levofloxacin 500mg daily 
+ metronidazole 500mg 
PO BID * 14days; 
followed by amoxicillin-
clavulanic acid 875mg PO 
BID * 7 days 
Managed as outpatient No 
21 84M 
 
Cardiomyopathy with 
ICD, COPD, OA, 
asthma 
Right arm R/O infection S. pseudintermedius Expectant management Managed as outpatient, no 
infection diagnosed 
No 
22 67F  DM, COPD, PVD, 
CAD, HTN, OP, gout, 
CVA  
Right leg SSTI, R/O fungal 
infection 
S. aureus (MSSA) 
S. pseudintermedius 
Cephalexin 500mg PO 
QID * 5 days  
Managed as outpatient No 
23 52M  
 
Dyslipidemia Ear  Otitis externa Group B Streptococcus, S. 
pseudintermedius 
Cephalexin 500mg PO 
QID * 10 days  
Managed as outpatient No 
24 58F 
 
DM on insulin, 
obesity, HTN, left heel 
ulcer, neuropathy 
Left heel  SSTI  S. anxious 
E. faecalis 
S. pseudintermedius  
Tissue debridement + 
antibiotics: fluconazole 
100mg PO daily * 3 days; 
followed by cefazolin 2g 
IV q8h + metronidazole 
500mg PO BID * 5 days; 
followed by ciprofloxacin 
500mg PO BID * 3 weeks; 
followed by cefazolin 2g 
IV q8h * 5 days 
Managed as outpatient No 
Abbreviations: Afib – atrial fibrillation; CAD – coronary artery disease; CHF – congestive heart failure; COPD – chronic obstructive 
pulmonary disease; CVA – cerebral vascular accident; DM – Diabetes mellitus; DVT – deep vein thrombosis; ICD – implantable 
cardiac defibrillator; HTN – Hypertension;  OA – osteoarthritis; OP – osteoporosis; PVD – peripheral vascular disease; RA – 
Rheumatoid arthritis; SSTI – skin and soft tissue infection; GPC – Gram positive cocci; GNB – Gram negative bacilli; GNEB – Gram 
negative enteric bacilli; MSSA – methicillin-sensitive Staphylococcus aureus; CoNS – coagulase negative S. aureus; spp – species; IV 
– intravenous; PO – per oral; BID – twice daily; TID – three times daily; QID – Four times daily ,ESRD – end stage of renal diseas
8
4
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Table 4.2: Summary of site of infection, antimicrobial resistant phenotypes, and multilocus sequence 
types of clinical Staphylococcus pseudintermedius isolates in Calgary. 
 SITE OF INFECTION ANTIMICROBIAL SUSCEPTIBILITY 
PROFILE 
ALLELIC 
PROFILE 
ST 
1 Neck /cellulitis Pan-Susceptible 3-2-6-1-11-1-2 504 
2 Superficial wound/leg AMP, PEN, TET, ERY, CLI 1-9-1-1-3-1-1 505 
3 Drainage umbilicus Pan-Susceptible 5-26-2-1-7-5-2 506 
4 Arterial line blood AMP, PEN 1-64-5-1-5-1-2 513 
5 Sterile fluid bursa MRSP, TET, ERY, CLI, GEN, SXT, LEV, 
MXF, CIP,  
3-11-2-24-20-1-1 181 
6 Skin AMP, PEN 5-24-2-20-25-2-2 512 
7 Sternum Pan-Susceptible 6-11-1-1-8-2-1 217 
8 Bronchial washing AMP, PEN 15-24-2-1-1-1-2 223 
9 Superficial wound/ knee AMP, PEN 1-13-4-1-7-1-2 507 
10 Superficial wound/ foot Pan-Susceptible 3-2-2-1-8-4-1 508 
11 Superficial wound/ leg AMP, PEN, ERY, CLI, CHL, 4-65-3-1-11-1-1 514 
12 Superficial wound/ toe AMP, PEN, TET 1-7-1-20-11-1-2 327 
13 Superficial wound/ foot AMP, PEN 13-2-1-1-13-1-2 200 
14 Superficial wound/ foot AMP, PEN 5-9-2-1-1-1-2 515 
15 Superficial wound / toe AMP, PEN, GEN 1-10-4-8-7-1-2 476 
16 Superficial wound / foot MRSP, ERY, CLI, GEN, SXT, LEV, MXF, CIP 3-9-1-2-1-2-1 71 
17 Superficial wound / toe AMP, PEN 3-2-2-4-10-2-2 509 
18 Left knee synovial fluid MRSP, TET, ERY, CLI, GEN, SXT, LEV, 
MXF, CIP 
3-11-2-24-20-1-1 181 
19 Right stump sores AMP, PEN, TET 4-9-1-44-11-1-1 516 
20 Superficial wound/ leg  MRSP, ERY, CLI, SXT, LEV, MXF, CIP 3-9-1-2-1-2-1 71 
21 Drainage right leg AMP, PEN 5-7-7-2-1-1-2 510 
22 Superficial wound / arm Pan-Susceptible 3-7-4-2-7-1-1 511 
23 Superficial wound / leg PEN 5-7-3-1-21-1-2 517 
24 Ear infection Pan-Susceptible 22-66-14-2-7-1-1 518 
25 Superficial wound / foot MRSP, ERY, CLI, SXT, LEV, MXF, CIP 3-9-1-2-1-2-1 71 
26 Deep wound/foot Pan-Susceptible 2-7-2-1-1-4-2 519 
27 Superficial wound / leg MRSP, ERY, CLI, GEN, SXT, LEV, MXF, CIP 3-9-1-2-1-2-1 71 
 
AMP - ampicillin; PEN - penicillin; MRSP - methicllin resistant, TET - tetracycline; ERY - 
erythromycin; CLI - clindamycin; CHL - chloramphenicol; GEN - gentamicin; SXT - 
trimethoprim + sulfamethoxazole; LEV - levofloxacin; CIP - ciprofloxacin; MXF - 
moxifloxacin. Allelic profiles: ack, cpn60, fdh, pta, purA, sar and tuf. 
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4.5 Discussion 
Although S. pseudintermedius is a recently identified species, it has likely been present for far 
longer and is an important pathogen of zoonotic origin. This study reflects the single largest 
collection to date of human S. pseudintermedius clinical cases and isolates in the literature. 
Staphylococcus intermedius was originally described in 1976 but it underwent reclassification 
upon identification of S. pseudintermedius in 2005 (Devriese et al., 2005). Since this time, 
isolates in the S. intermedius group were divided into one of three clusters: S. intermedius, S. 
pseudintermedius, and S. delphini (Sasaki et al., 2007b). S. pseudintermedius is a normal 
inhabitant and frequent opportunistic pathogen of canines and other companion animals. Of the 
24 clinical cases, 91.7% had confirmed contact with dogs temporally with infection reflecting the 
zoonotic transmission characteristics of this species.  
 
Studies of S. pseudintermedius have demonstrated it to be a leading cause of soft tissue and ear 
infections, as well as infections of other body tissues or cavities in canine and feline species 
(Abraham et al., 2007; Griffeth et al., 2008). In support of this, S. pseudintermedius has a 
number of important similar phenotypic characteristics to S. aureus. Notably, S. 
pseudintermedius characteristics include coagulase, protease, DNase, β-haemolysin, and 
exfoliative toxin production which all support the pathogenic potential of this species 
(Fitzgerald, 2009). Similarly, in our series, S. pseudintermedius was most commonly implicated 
in skin and soft tissue infections in humans. To note, in our case series of 4 patients were 
diagnosed as having non-infectious etiology. The majority of infections did not require 
hospitalization and were managed with short courses of oral antibiotic therapies. In two cases 
with MRSP isolates, no specific MRSP-directed therapy was used in the management. Given the 
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polymicrobial nature of the cultures in most of the clinical cases, the virulence of human S. 
pseudintermedius infections in human may differ than in those of companion animals, where this 
organism is often the primary pathogen. However, since two invasive infections occurred in this 
series, S. pseudintermedius certainly has the potential to be virulent in the human host.  
 
MRSP has been an emerging concern in veterinary medicine in recent years (Weese and van 
Duijkeren, 2010), and similar to S. aureus, methicillin resistance is mediated by the mecA gene 
which encodes production of a modified penicillin-binding protein (PBP). The mecA gene is 
located on a mobile element of the bacterial chromosome called the ‘staphylococcal 
chromosomal cassette’ (SCCmec) and is readily transferred between different Staphylococcal 
species. Almost a third of S. pseudintermedius isolates in our case series [22.2% (6/27)] had 
isolates which demonstrated methicillin resistance in addition to being multi-drug resistant to 
other antibiotic classes including macrolides, sulfonamides, and fluoroquinolones. Four of the 
MRSP isolates had oxacillin MICs of 0.5μg/ml and 1μg/ml below the S. aureus oxacillin 
breakpoint of 4 μg/ml in accordance with standard criteria to prevent misclassification as 
methicillin susceptible isolates. In our case series, S. pseudintermedius was most commonly a 
component of a polymicrobial environment and frequently with other Staphylococcal species. As 
up to 90% of healthy dogs may be colonized with S. pseudintermedius (Rubin and Chirino-Trejo, 
2011; Talan et al., 1989a; Talan et al., 1989b), if the human transmission is common, a 
proportion of methicillin resistance observed in S. aureus and another coagulase-negative 
Staphylococcal species may reflect the transfer from S. pseudintermedius. However, as the 
absolute incidence S. pseudintermedius was very low the pathogencity, potential for inter-species 
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transfer, and the clinical impact in monomicrobial and polymicrobial infections requires further 
study.  
 
Our MLST typing revealed that all MRSP isolates had sequence types commonly identified in 
Europe (ST71 and ST181), and the North American associated MRSP (ST68) was not identified 
despite being previously reported in dogs in Canada (Kjellman et al., 2015; Perreten et al., 2010). 
Sequence types 71 and 181 are widely associated with multidrug resistance; ST71 specifically 
has been associated with resistance to macrolides, sulfonamides and the fluoroquinolones in 
Europe (Moodley et al., 2013). Fortunately, resistance to drugs active against methicillin 
resistant isolates such as vancomycin, daptomycin, linezolid or quinupristin + dalfopristin has 
not yet been reported. We too did not observe this in our series. The diversity of strains identified 
among MSSP indicated that these infections were likely community acquired and are 
epidemiologically unrelated.  
 
4.6 Conclusion 
In conclusion, the introduction of highly discriminatory laboratory methods has allowed S. 
pseudintermedius to be increasingly recognized as a potential zoonosis of canine origin.  In the 
largest case series to date of human infections with S. pseudintermedius, we demonstrated that it 
is most commonly a member of a polymicrobial environment, likely transmitted from companion 
animals, and implicated in skin and soft tissue infections. S. pseudintermedius was most 
commonly associated with mild-moderate SSTI similar to those described in the literature for 
canine species. Certainly, as it has virulence characteristics similar to that of S. aureus, the 
potential for invasive infections exists. Rising methicillin resistance in S. pseudintermedius and 
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the ability for transfer between Staphylococcal species may have significant implications for 
rising antimicrobial resistance and infection management. 
 
4.7 Transition Statement  
The emergence of antimicrobial resistance including MRSP, which is often multi drug resistant, 
limits the ability of clinicians to use currently available antimicrobials for therapy. Veterinarians 
are therefore increasingly reliant on non-beta-lactam drugs including chloramphenicol, 
tetracycline, and trimethoprim+ sulfamethoxazole for treating resistant Staphylococcus 
pseudintermedius infections. Surprisingly, in our previous studies, we have not seen an isolate 
which is resistant to all three drug classes, indicating that reasonable treatment options are still 
available for multi drug resistant infections. At present, tetracycline is used as an indicator for 
doxycycline and minocycline which are more commonly used drugs in dogs. Although we know 
that the tetracyclines differ in their chemical structure and binding affinity to the drug target, the 
difference in susceptibility to drugs within this class have not been evaluated. Furthermore, the 
reliability of tetracycline as an indicator of resistance to second generation tetracycline has not 
been evaluated. There are multiple mechanisms of tetracycline resistance although these are ill-
defined in Staphylococcus pseudintermedius. Therefore, the next experiments were designed to 
understand the mechanism of resistance to tetracyclines in S. pseudintermedius and to evaluate 
the possibility doxycycline or minocycline to treat infections resistance to tetracycline.  
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5.1 Abstract 
Antimicrobial resistance including methicillin resistance is emerging in S. pseudintermedius, 
non-β-lactams such as tetracycline, chloramphenicol, and sulfa-trimethoprim are therefore 
widely used in companion animals. The second generation tetracyclines such as doxycycline and 
minocycline, are the primary tetracyclines used in companion animal practice. The Clinical and 
Laboratory Standards Institute recommends tetracycline as an indicator drug for doxycycline and 
minocycline in antimicrobial susceptibility testing. For S. pseudintermedius, neither the 
reliability of tetracycline as an indicator drug nor the contribution of recognized resistance genes 
to phenotypic resistance has been determined. Our objectives were to determine the reliability of 
tetracycline as a surrogate drug for detecting resistance to doxycycline and minocycline and to 
describe the association between resistance genes and resistance phenotypes. 
Antimicrobial susceptibility testing was performed for tetracycline, doxycycline, and 
minocycline in 521 S. pseudintermedius isolates and MICs were determined for a subset of 70 
isolates by agar dilution. Tetracycline resistance genes were screened by PCR and a subset of 18 
isolates representing the breadth of susceptibility and gene profiles were sequenced using the 
Illumina MiSeq platform. Genomes were interrogated for recognized resistance genes using 
online databases. Eight isolates possessing tetM were further characterized; tetM copy number 
and expression level were measured using an SYBR Green-based qPCR assay.  
Although the majority of tetracycline resistant isolates were also resistant to doxycycline and 
minocycline, two remained susceptible to both doxycycline and minocycline, while a third was 
tetracycline and doxycycline resistant and susceptible to minocycline. All resistant isolates 
contained at least one recognized resistance gene; tetM was most commonly identified while 
tetK and tetL were each found in single isolates. Among isolates only possessing tetM, a wide 
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range tetracycline (2->32µg/ml), doxycycline (0.25-16µg/ml) and minocycline (0.25-16µg/ml) 
MICs were observed. Differences in tetM copy number were not significantly associated with 
tetracycline or doxycycline MIC, nor were differences in the expression of tetM. In conclusion, 
tetracycline may be an inadequate indicator of resistance to second generation tetracyclines and 
the routine inclusion of doxycycline or minocycline on antimicrobial test panels is 
recommended. The phenotypic diversity in susceptibility to the tetracyclines cannot be solely 
explained by the presence or absence of resistance genes. Additional work is clearly required to 
understand the mechanisms of resistance to the tetracyclines in S. pseudintermedius.  
 
5.2 Introduction 
Staphylococcus pseudintermedius colonizes in 90% of healthy dogs (Rubin and Chirino-Trejo, 
2011). It is an opportunistic pathogen, inhabitants in mucous membranes and skin (Bannoehr and 
Guardabassi, 2012). Importantly, S. pseudintermedius is the most common cause of pyoderma, 
otitis externa and the second common cause of urinary tract infections in dogs (Rubin and 
Chirino-Trejo, 2011). Antimicrobial resistance is emerging in S. pseudintermedius which is a 
growing problem for the treatment of bacterial infections (Schwarz et al., 2016). The β-lactams 
are frequently prescribed by veterinarians and physicians in Canada for common infections 
caused by Gram positive bacteria including Staphylococci (CARSSR, 2016). Some authors have 
suggested that as β-lactam resistance emerges, veterinarians are becoming less likely to prescribe 
this class of drug in companion animals (Schnedeker et al., 2017).  MRSP is often multidrug 
resistant and rising resistance is reported to the fluoroquinolones, aminoglycosides, macrolides, 
and sulfonamides (Kadlec et al., 2016). The use of last line of defense drugs such as vancomycin 
and linezolid, which is designated for human use, is anecdotally still rare in veterinary medicine. 
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As such, therapeutic alternatives are limited for veterinarians to treat resistant bacterial 
infections. Therefore, the effective utilization of currently available antibiotics such as 
tetracycline and sulfamethoxazole is particularly important in veterinary medicine as in some 
cases these may be the only reasonable alternatives to the β-lactams. 
Tetracycline, discovered in the late 1940s, is a broad-spectrum antibiotic which is also used 
against atypical bacterial infections such as Rickettsiales and spirochetes, and also as an 
antiprotozoal (Chopra and Roberts, 2001). The first-generation tetracyclines, chlortetracycline, 
and oxytetracycline are used mainly in agricultural animals (Chopra and Roberts, 2001). 
Currently, doxycycline and minocycline are the most commonly used drugs in companion 
animals (Hnot et al., 2015). These two are important alternatives for treating MRSP infections in 
dogs, previous studies have been reported that 35-50% of MRSP remained susceptible to 
doxycycline and minocycline (Humphries et al., 2016; Kawakami et al., 2010). According to the 
CLSI, tetracycline is being used as an indicator agent for detecting resistance to the second 
generation tetracyclines (CLSI, 2016). As described by EUCAST, isolates susceptible to 
tetracycline should also be considered to be susceptible to doxycycline and minocycline while 
those resistant to tetracycline may remain susceptible to doxycycline and minocycline 
(EUCAST, 2017). The CLSI states that isolates which are intermediately resistant to tetracycline 
should be described as “may be susceptible for doxycycline” (CLSI, 2015). The correlation of 
resistance to tetracycline and doxycycline is clearly ill-defined and requires further investigation. 
Resistance to tetracycline occurs by four main mechanisms. In S. pseudintermedius tetM is 
reported to be the most common. TetM is a ribosomal protection protein and acts on the amino 
acyl-tRNA ribosome complex and confers resistance by displacing tetracycline (Chopra and 
Roberts, 2001). This protein has five domains (I – V), domain IV is hypothesized to localize to 
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the “A” site of the 30S ribosomal subunit (Connell et al., 2003). Associations between domain III 
and the 30S ribosomal subunit and decoding sites have also been observed, and mutations in this 
region of tetM have been associated with elevated tetracycline MICs in E. faecalis (Dönhöfer A, 
2012). Similarly, TetO is another ribosomal protection protein which has a similar function to 
TetM but is less commonly found in S. pseudintermedius. Efflux-mediated resistance to 
tetracycline is encoded by the tetK and tetL genes are frequently found on plasmids in 
Staphylococci (Chopra and Roberts, 2001; Roberts, 1996). These four genes are the only 
tetracycline resistance determinants so far identified in S. pseudintermedius (Kadlec and 
Schwarz, 2012).  
Because, tetracycline acts by binding to the ribosome and interacting with the 16S rRNA and 
small subunit ribosomal proteins, mutations in these structures have been related to elevated 
tetracycline MICs (Chopra and Roberts, 2001; Gerrits et al., 2002; Nonaka et al., 2005). The 
small subunit ribosomal proteins S7, S3, S8, S14, and S19 also interact with tetracycline (Oehler 
et al., 1997). It has therefore been suggested that specific 16S rRNA SNPs, and mutations in the 
S7 and S12 protein sequences can affect these interactions and therefore tetracycline binding 
affinity (Moazed and Noller, 1987). However, mutations in these genes associated with 
tetracycline resistance have not been reported in S. pseudintermedius. Therefore, the first 
objective of the study was to determine the reliability of tetracycline as an indicator for detecting 
susceptibility to doxycycline and minocycline in S. pseudintermedius. The second objective was 
to understand the mechanism of resistance to tetracycline and to describe the association between 
resistance genes and phenotypic resistance in S. pseudintermedius.  
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5.3 Material and Methods 
5.3.1 Antimicrobial susceptible testing and identification of resistance genes 
Antimicrobial susceptibility testing was done for 521 S. pseudintermedius isolates from dogs for 
tetracycline, doxycycline, and minocycline by disk diffusion according to the method described 
(CLSI, 2016). The MICs were determined for a subset of 70 tetracycline susceptible and resistant 
isolates by agar dilution (CLSI, 2012a). The results were interpreted using the CLSI veterinary 
clinical breakpoints except for minocycline, the clinical breakpoint for doxycycline was used for 
minocycline (CLSI, 2015). These 70 isolates were also screened for tetK, tetM, tetO, and tetL by 
PCR using primers designed and optimized in this study (Table 5.1). PCR products were 
sequenced (Macrogen Inc. Seoul, Korea), the chromatogram quality of each sequence was 
inspected using pregap and contigs were then aligned using gap (Staden packages). The 
consensus sequences were examined by BLAST in the NCBI database to confirm the identity of 
the amplicon. 
96 
 
Table 5.1: The primer sequences, NCBI accession number of nucleotide sequence and products 
size for conventional PCR and qPCR to screen tet gene in the study. 
Gene Primer (5’ to 3’) Reference sequences 
used to design primers 
Product size (bp) 
tetK F: ATCTGCTGCATTCCCTTCAC 
R: GCAAACTCATTCCAGAAGCA 
456769 818  
tetM F: ACACGCCAGGACATATGGAT 
R: GCAAAGTTCAGACKGACCTC 
X90939 530  
tetO F: GATGTGTGTTCCGACAAACG 
R: CCATAAAGAACCCCCTCCAT 
M20925 
 
573  
tetL F: CTGCATTTCCAGCACTCGTA 
R: CGAAAGCCCACCTAAAACAA 
17153 737  
tetM* F: TGGGCTTCCATTGGTTTATC  
R: TCCGTCACATTCCAACCATA 
MSSP34 tetM sequence (in 
this study) 
163  
Primers for qPCR*  
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5.3.2 Whole genome sequencing 
Based on the breadth of phenotypic resistance and genotypic characterization, a subset of the 
collection (n=18) were selected for WGS. The collection included resistant isolates with higher 
and lower MICs and isolates which were susceptible to tetracycline. DNA was extracted by the 
modified salting out method, DNA concentration was measured by QubitTM assay (Invitrogen) 
and quality was evaluated by running genomic DNA in 1% agarose gel (Martin-Platero et al., 
2007). The WGS was run on the Illumina MiSeq platform on a V2 chip using the Nextera XT 
indexing kit for multiple samples.  
The quality of genomes was analyzed by FASTQ and de-novo assembly by Velvet short 
sequence alignment (Table 5.3). Assembled genomes were annotated in RAST-OMGE using S. 
pseudintermedius ED 99 as a reference (NCBI Accession number: CP002478). The genomes 
were interrogated for recognized resistance genes using the online resistant gene databases 
ResFinder (genomicepidemilogy.org) and CARD (Comprehensive Antimicrobial Resistance 
Database – card. macmaster.ca) (Jia et al., 2017; Zankari et al., 2012). The nucleotide sequences 
of 16S rRNA were examined for the mutations comparing to the sequences from susceptible 
isolates in this study. In addition, sequences of small subunit proteins were investigated once 
aligned with susceptible isolates (CLC Genomic Workbench 9.5.1).  
 
5.3.3 Phylogenetic analysis 
tetM sequences were compared to each other (n=9) and to a set of previously published reference 
sequences from NCBI GenBank. Full-length amino acid sequences (639 aa), were aligned using 
MUSCLE, and a phylogenetic tree was constructed by maximum likelihood methods in MEGA 7 
(Kumar et al., 2016). 
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5.3.4 Optimization of qPCR for tetM and quantification of tetM copy number 
Primers for qPCR targeting tetM were designed based on the tetM sequence of the MSSP34 
sequenced in this study. Primers from three previously published reference genes were selected 
as gyrB, rho, and recA (Crawford et al., 2016). The PCR protocol four genes were optimized in 
this study (Table 5.1). The purified PCR products were cloned into the pGEM+6 plasmid 
according to the manufacturer’s instructions and transformed into the competent E. coli as 
described (pGEM®-T Easy Vector Systems: Promega). The competent E. coli were grown in LB 
agar (100mg/L of ampicillin) and the plasmid was extracted by standard extraction kit EZ98-10 
Spin column Plasmid DNA MiniPrepskit, Bio Basic International, Version 20.0 Rev3/23/2015: 
Molecular Biology Kit) and confirmed the size of plasmid running in 1% gel. The qPCR 
protocols were optimized for tetM and three reference genes. The DNA was serially diluted from 
100 to 10-10, a standard curve was run for tetM and three reference gene and primer efficiency 
were calculated (Table 5.4). 
Nine S. pseudintermedius isolates were run in the optimized qPCR was based on the standard 
curve for all four genes in Biorad master mix (iQ SYBR Green Supermix, 170-8882: BIO-RAD) 
using known positive controls (Protocol: 950C for 3 minutes, 40 cycles of 950C for 10 Seconds, 
550C for 10 Seconds,720C for 30 Seconds and 950C for 10 Seconds). However, for gyrB, an 
annealing temperature of 650C was used.  
To measure tetM copy, Staphylococcus pseudintermedius were cultured on 5% sheep blood agar 
incubated for 24 hours at 350C. A 100µl of McFarland 0.5 were inoculated into a 10 ml of TSB 
with 2% dextrose and incubated for 4 hours at 350C in shaking incubator (220rpm). DNA was 
extracted from 1 ml using the modified salting out method and the concentration of DNA was 
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measured by Nanodrop (NanoDrop: ND-2000c: Thermo Fisher)  and QubitTM assay (Martin-
Platero et al., 2007). To determine the tetM copy number, extracted DNA was used as a template 
for qPCR reactions, for gyrB and recA gene, an additional 100-fold dilution was made prior to 
amplification due to the high copy number. The qPCR was run for tetM and three reference 
genes in SYBR green method (iQ SYBR Green Supermix, 170-8882: BIO-RAD). The final copy 
number of each gene was calculated considering all the dilution factors. 
 
5.3.5 tetM gene expression 
The tetM gene expression was then measured in 8 isolates selected to represent a diversity of 
minimum inhibitory concentration to tetracycline and doxycycline, each isolate was tested once 
and no replicates were included. Expression was measured following 150 minutes of exposure to 
three concentrations of tetracycline and doxycycline (0µg/ml, 0.01µg/ml, and 1µg/ml: based on 
MICs for tetracyclines of the isolates) as seen in Figure 5.1. RNA was extracted using the ALL 
PREP DNA/RNA MINI KIT (Qiagen) with modification of following steps. 1 ml of broth 
culture was centrifuged and the cell pellet was resuspended in 100 ml of TES for enzymatic 
digestions (lysozyme, lysostaphin, mutanolysin) as described by modified salting out method. A 
proteinase K digestion was then done in RLT plus buffer, the enzymatic mixture was inactivated 
by incubating at 800C for 15 minutes. The extracted RNA was purified using the DNA-free kit as 
described (Life Technologies, AM2235,1000U). The quality of RNA was tested by Nanodrop 
(NanoDrop: ND-2000c) and the Agilent RNA 6000 Nano reagent by Bioanalyzer (Agilent 2100 
Bioanalyzer). RNA was normalized according to the Nanodrop reading (NanoDrop: ND-2000c: 
Thermo Fisher) prior to the cDNA synthesis using the iScript cDNA Synthesis kit 
(BIORAD;1708891). Quantification of tetM cDNA transcripts was then done using the same 
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SYBR Green-based qPCR assay (iQ SYBR Green Supermix, 170-8882: BIO-RAD). Transcripts 
of the three reference genes were also quantified.  
 
5.3.6 Statistical analysis 
The reference genes were evaluated using Normfinder and GeneKeeper prior for the statical 
analysis. The results of tetM copy number and gene expression were determined relative to recA. 
The final copy numbers were calculated as a ratio to recA, as the reference or control for gene 
fold calculation. The association of tet gene on different MICs category were analyzed by the 
chi-square test. The gene copy number and tetM gene expression on MICs for tetracycline and 
doxycycline were analyzed by Mann-Whitney test using SPSS 21.  
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Figure 5.1: Flow diagram for the tetM gene expression study in different concentration of 
tetracycline and doxycycline in S. pseudintermedius. 
Two groups of tetracycline resistant isolates, those with high (MICs 8 µg/ml) and low (MICs 
4 µg/ml) MICs to both tetracycline and doxycycline were compared. Expression of tetM was 
measured at two drug concentrations (0.01µg/ml and 1 µg/ml) and a no antibiotic control. 
Expression was measured after exposure to each experimental condition for 150 minutes at 350C 
for 220 rpm shaking incubator.   
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5.4 Results 
A great diversity of resistance phenotypes for tetracycline, doxycycline, and minocycline were 
found in this study. Two isolates (MRSP03, MSSP16) were resistant to tetracycline and 
susceptible to doxycycline and minocycline (Table 5.2). One isolate (RSP63A1c) was resistant to 
both tetracycline and doxycycline and susceptible to minocycline (Table 5.2). All isolates which 
phenotypically resistant to tetracycline possessed at least one resistance gene, while no resistance 
genes were identified in fully susceptible isolates except in SP16 which possessed a sequence 
with >80% similarity to tet38 (Table 5.2). The results of whole genome sequencing were 
consistent with PCR assays and additional resistance genes were not identified by exploring in 
online resistance databases. The tetM gene was most commonly identified and was present in all 
resistant isolates except for RSP63A1c where the only tetL was found. Another isolate, 
MRSP11, possessed both tetK and tetM (Table 5.2). No isolates containing tetO were identified. 
Among isolates only possessing tetM, a wide range of MICs for tetracycline (2->32µg/ml), 
doxycycline (0.25-16µg/ml) and minocycline (0.25-16µg/ml) were observed.  
Resistant isolates were divided into two MIC categories: 1. low level of resistant and 2. high-
level resistant (Table 5.2). For tetracycline, isolates with MICs ≤4µg/ml were classified as low-
level resistant and MICs ≥8 were classified as high-level resistant. For doxycycline, isolates with 
MICs ≤4µg/ml were classified as low-level resistant while those with MICs ≥8µg/ml were 
classified as high-level resistant. To investigate the diversity of resistance to tetracyclines, we 
first examined tetM protein sequences and two distinct clusters were found (Figures 5.2). 
MRSP03, MSSP16, MSSP18, and MSSP15 were highly similar (Cluster 1) and MSSP11, 
MSSP34, MSSP08, RSA09A1a and MRSP 11 formed a second group (Cluster 2). One outlier 
isolate, SP03, was dissimilar from all other sequences identified in our collection. Interestingly, 
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all previously published TetM sequences from S. pseudintermedius also fell into these two 
clusters; interestingly both clusters included isolates with high and low MICs to tetracycline and 
doxycycline (Figure 5.2). The TetM sequence from SP03 was divergent from the other isolates 
included in this study and clustered with previously published TetM sequences from E. feacium. 
When the promoter region of tetM was examined, no association with tetracycline or 
doxycycline MIC category was identified (Figure 5.6).  
A significant association between tetM copy number and MIC for tetracycline were not found 
(Figure 5.3). Furthermore, no significant differences in fold changes in tetM expression were 
identified between low MIC and high MIC categories for either tetracycline or doxycycline 
(Figures 5.4 & 5.5). Interestingly, tetM expression level was concentration-dependent increasing 
significantly following exposure to higher concentrations of doxycycline (P = 0.02) and 
insignificantly with exposure to higher concentrations of tetracycline (P = 0.172).   
When the ribosomal small subunit protein sequences were examined, a silent mutation was 
observed in S12 was found in one isolate in this collection, while the sequences of the S3, S7, 
S8, S14, and S19 proteins were identical. A similar observation was made for the16S rRNA 
sequences, all isolates had the same nucleotide sequence at positions which were previously 
shown to confer resistance in E. coli and P. acne (Table 5.5) (Oehler et al., 1997; Ross et al., 
1998).  
Finally, the mgrA and sav1866 genes which have been previously reported as regulatory genes 
and efflux-mediated resistance for tetracycline respectively were identified in both resistant and 
susceptible isolates (Dawson and Locher, 2007; Truong-Bolduc et al., 2005). No meaningful 
association was found between the presence of these genes and resistance to tetracycline in S. 
pseudintermedius.   
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Table 5.2: Summary of MICs for tetracyclines and resistance gene found by PCR and WGS 
followed by exploring in the online antimicrobial resistance databases. 
Isolate ID  
MICs by agar dilution test (µg/ml) 
 
Genes 
detected by 
conventional 
PCR 
Resistance 
gene 
identified in 
whole genome  tetracycline doxycycline minocycline 
RSA100A1a 0.12 <0.03 <0.03 - - 
RSA05A1b  0.12 <0.03 <0.03 - - 
SP16 0.12 <0.03 <0.03 - tet38 
RSA89A1b 0.12 0.06 <0.03 - - 
RSA08A1b 0.12 0.06 <0.03 - - 
SP53 0.25 0.06 0.06 - - 
MRSP03 2 0.25 0.25 tetM tetM 
MSSP15 4 1 0.5 tetM tetM 
MSSP16 2 0.25 0.06 tetM tetM 
MSSP11 8 8 0.5 tetM tetM 
MSSP18 16 4 0.5 tetM tetM 
RSA67A1a 32 4 0.5 tetM tetM 
RSP09A1a  32 8 4 tetM tetM 
RSP63A1c 32 4 0.06 tetL tetL 
MSSP08 >32 8 8 tetM tetM 
MSSP34 >32 8 8 tetM tetM 
MRSP11 >32 16 2 tetM, tetK  tetM, tetK  
SP03 >32 16 16 tetM tetM 
 
Isolates with MICs in the susceptible range are coloured in green. Isolates with MICs indicating 
resistance are highlighted either yellow (low-level resistance) or red (high-level resistance). 
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Figure 5.2: Phylogenetic tree of TetM protein sequences from in this study with published 
protein sequences in selected bacterial species in NCBI (MIC category was displayed according 
to the tetracycline). 
* S. pseudintermedius TetM sequences which were retrieved from NCBI GenBank.
 KZK27301.1 TetM Staphylococcus pseudintermedius
 KZK21073.TetM Staphylococcus pseudintermedius
 ADX77642.1 TetM Staphylococcus pseudintermedius ED99
 ABV57476.1 TetM Lactobacillus sakei
 AIU85825.1 TetM Staphylococcus aureus subsp. aureus
 RSA67A1c TetM (MIC:32)
 MSSP15 TetM (MIC:4)
 KZK20695.1 TetM Staphylococcus pseudintermedius
 MRSP03 TetM (MIC:2)
 MSSP16 TetM (MIC:2)
 MSSP18 TetM (MIC:16)
 ACF08831.1 TetM Klebsiella pneumoniae
 AAY62601.1 TetM Lactococcus lactis subsp. lactis
 AAY62599.1 TetM Lactococcus lactis subsp. lactis
 AJP18150.1 TetM Bacillus subtilis
 ANS90560.1TetM Staphylococcus pseudintermedius
 ANS88620.1 TetM Staphylococcus pseudintermedius
 MSSP11 TetM (MIC:8)
 MSSP34 TetM (MIC:32)
 MSSP08 TetM (MIC:32)
 RSA09A1a TetM (MIC: 32)
 KAI53553.1 TetM Staphylococcus aureus VET1917S
 AMQ17269.1 TetM Streptococcus agalactiae
 ABG21123.1 TetM Escherichia coli
 ADV06640.1 TetM Staphylococcus pseudintermedius HKU10-03
 MRSP11 TetM (MIC:32)
 AKJ52741.1 TetM Mycoplasma hominis
 APJ33269.1 TetM Streptococcus pneumoniae
 KEQ37480.1 TetM Streptococcus mitis
 YP 003600433.1 TetM Neisseria gonorrhoeae
 ABD46539.1 TetM Acinetobacter junii
 ABI81214.1 TetM Vibrio sp.
 AIL03464.1 TetM Enterococcus faecalis
 BAB71968.1 TetM Clostridium septicum
 KYH29562.1 TetM Clostridium colicanis
 YP 001086983.1 TetM Clostridioides difficile
 ADA62733.1 TetM Enterococcus faecium
 SP03 TetM (MIC32)
 CUM89219.1 TetM Eubacterium hallii
 CNC92611.1 TetM Streptococcus agalactiae
 CYV70921.1 TetM Streptococcus suis
 CUP42488.1 Tn916 Coprococcus comes
 CUQ44819.1 TetM Flavonifractor plautii
Cluster 1  
Cluster 2  
High MICs       
Low MICs        
SP* 
seque
nces   
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Table 5.3: Summary of WGS of Staphylococcus pseudintermedius isolates in this study (n=18). 
ID Assembly 
size 
GC 
content% 
Contigs Contigs 
N50 
scaffolds Scaffolds 
N50 
MSSP18 2500648 37.62 83 58578 75 67540 
MSSP34 2575334 37.51 92 62957 84 68481 
RSA100A1a 2517592 37.68 52 125796 41 125796 
MSSP11 2399811 37.87 98 56695 75 74150 
RSA63A1c 2497917 37.69 56 117925 47 127519 
RSA67A1a 2489950 37.62 78 67706 67 96944 
RSA89A1b 2548371 37.53 64 127844 47 156805 
RSA05A1b 2599913 37.34 99 125626 81 125626 
RSP09A1a 2551544 37.62 63 90312 50 123064 
SP16 2384965 35.86 50 117709 34 125619 
MRSP03 2610195 37.58 141 46522 118 56143 
MSSP08 2617347 37.5 103 71264 77 94379 
SP03 2096021 39.62 63 91911 45 118713 
SP53 2427959 37.72 92 54637 80 62668 
MSSP15 2546900 37.43 78 70554 64 116468 
MSSP16 2780662 37.22 94 57797 81 72248 
MRSP11 2767609 37.25 125 62978 113 64561 
RSA08A1b 2545616 37.52 69 83399 58 89055 
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Table 5.4: Summary of primer efficiency and coefficient of correlation (R2) for tetM and the 
three reference genes used for the standard curve for qPCR. 
Name of the gene protocol R2 Primer efficiency % 
tetM In this study 0.990 95.7 
gyrB In this study 0.996 102.5 
rho In this study 0.994 96.2 
recA In this study 0.994 94 
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Table 5.5: Comparison of the specific nucleotide locations in S. pseudintermedius into the 
published information in E. coli and Propionibacterium to determine association for the 
resistance to tetracycline. 
The organism Nucleotide position in the 
published 
Nucleotide position in 
examined in this study 
Reference 
E. coli  G693 G693 Oehler et al, 1997 
 A892 C892  
 G890 G890  
 U1052 G1052  
 C1054 G1054  
 G1300 G1300  
 G1338 C1338  
P.acne  U1052 G1052 Ross et al,1998 
 C1054 G1054  
 G1058 G1058  
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Figure 5.3: Comparison of tetM copy number between isolates with high and low doxycycline 
and tetracycline MICs. 
 
The qPCR based quantification of tetM relative to the recA gene. Low (n=4) and high (n=5) 
level resistant isolates are compared. Isolates with doxycycline MICs of ≥4µg/ml and 
tetracycline MICs of ≥8µg/ml were considered to be high-level resistant.  
 
  
Low Low High High 
Tetracycline 
P = 0.81 P = 0.47 
=0.01µg/
ml 
Doxycycline 
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Figure 5.4: The tetM gene fold changes at different concentration tetracycline. 
The qPCR based quantification of tetM relative to the recA gene. Isolates with low (n=4) and 
high (n=4) level resistance were included and tetM expression was compared between these 
isolates on exposure to different tetracycline concentrations. Expression of tetM in isolates with 
low MICs (P = 0.15) and high MICs (P =0.56) did not differ significantly between tetracycline 
concentrations. 
  
  
Low Low High High 
 
0.01µg/ml 
1µg/ml 
P = 0.25 P = 0.25 
P = 0.17 
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Figure 5.5: The tetM gene fold changes at different concentration doxycycline. 
 
The qPCR based quantification of tetM relative to the recA gene. Isolates with low (n=4) and 
high (n=4) level resistance were included and tetM expression was compared between these 
isolates on exposure to different doxycycline concentrations. The fold changes expression 
between low MICs were P = 0.02 and high MICs were P =0.04 at different tetracycline 
concentration. Expression of tetM in isolates with low MICs (P = 0.02) and high MICs (P =0.04) 
differed significantly between doxycycline concentrations. 
 
  
Low Low High High 
0.01µg/ml 
1µg/ml 
P = 0.15 
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P = 0.02 
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Figure 5.6: Phylogenetic tree of the promoter region (flank region) of tetM gene with MIC for 
tetracycline. 
 
The sequences of the tetM promotor region (n=10) were extracted from whole genome 
sequences. These sequences formed two clusters, while SP03 was an outlier. Each cluster 
contained isolates with both high and low tetracycline MICs, which are indicated on the right.  
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5.5 Discussion 
Doxycycline and minocycline are the most commonly used tetracyclines in companion animals, 
while chlortetracycline and oxytetracycline are primarily used in agriculture (Chopra and 
Roberts, 2001). Although phenotypic resistance is being shown frequently, resistance 
mechanisms for the tetracyclines (including doxycycline, minocycline) have not been thoroughly 
investigated in Gram positive bacteria including S. pseudintermedius. The literature was limited 
to screening for genes by PCR/microarray and reporting simple presence/absence without a 
detailed description of the accompanying phenotype (Kadlec and Schwarz, 2012). Resistance to 
tetracycline does not concur always with doxycycline and minocycline in S. pseudintermedius 
and intermediate resistance to tetracycline may be susceptible for doxycycline in Staphylococci 
(CLSI, 2015). Minocycline has an additional C7-dimethylamino group on ring D which is shown 
noncovalent interaction with C1054 in the h34 helix of 16S rRNA, was shown 20 times more 
affinity to the ribosome (Nguyen et al., 2014). Second generation tetracycline is more lipophilic 
in nature than the parent compound, these differences may result in improved pharmacodynamic 
interactions and more potent antimicrobial activity (Nguyen et al., 2014). Tetracycline resistant 
isolates may, therefore, remain susceptible to doxycycline and minocycline which could remain 
effective treatment options for MRSP infections in dogs (Humphries et al., 2016).  
Consistent with previous studies tetM was the most commonly tetracycline resistance gene in 
this collection (Kadlec and Schwarz, 2012). Although all isolates possessing tetM were resistant 
to tetracycline, they were not always resistant to doxycycline and minocycline. A significant 
difference in tetM expression was not observed for tetracycline or doxycycline between high and 
low MIC categories in our collection of S. pseudintermedius.  
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The ribosomal protection protein TetM has been reported more than 50 different bacterial 
species, including Gram-positives, negatives and anaerobic bacteria (Connell et al., 2003; 
Dönhöfer A, 2012; Taylor and Chau, 1996). Diversity in the sequence of previously published 
TetM sequences was found, we were curious to see if these differences might be associated with 
phenotypic variation. Therefore, we constructed a TetM phylogenetic tree to compare these 
sequences to tetracycline and doxycycline MICs to see if an obvious association exists in S. 
pseudintermedius. Interestingly, we did not identify co-clustering of isolates by MIC category 
with TetM sequence suggesting that sequence diversity may not be responsible for the observed 
phenotypic diversity (Figure 5.2). However, SP03 did not cluster with rest of the sequence of the 
study or other S. pseudintermedius sequence deposited in GenBank. This particular sequence was 
most closely related to a tetM sequence from an E. faecium suggesting that in the case of this 
organism tetM may have been acquired from some other bacterial species. The high sequence 
diversity of tetM has been reported previously, this gene is reported to have a mosaic structure as 
a result of selection pressure on mobile genetic elements (Oggioni et al., 1996). Previous studies 
have found that both the carboxyl-terminal end and domain IV of TetM interact with the 23S and 
16S rRNA, mutations in these TetM structures may, therefore, be associated with alterations in 
the level of resistance conferred by this protein (Dönhöfer A, 2012). The mutations at specific 
nucleotides in 16S rRNA which previously found in E. coli and Propionibacterium acne were not 
identified in this study (Table 5.4) (Roberts, 1996).  Ross et al reported that G1058 to C mutation 
which resistance to tetracycline in Propionibacterium, (Taylor and Chau, 1996).  However, 
mutations at these sites were not found in S. pseudintermedius in this study.   
One isolate possessing the tetL efflux pump was resistant to both tetracycline and doxycycline 
but not minocycline; consistent with previous studies which demonstrated that minocycline is not 
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a substrate for this efflux pump (Nguyen et al., 2014). With one exception, no tetracycline 
resistance genes were found among fully susceptible isolates. The exception was one isolate 
possessing a gene with 86% identity to tet38, this putative resistance gene was identified by 
interrogating the genome of SP16 using the CARD database. This finding may indicate that the 
gene we identified may be a precursor of the tet38 resistance gene, or perhaps an orthologous 
gene which has since lost its function with respect to tetracycline resistance. In S. aureus, tet38 
encodes for efflux pump which confers tetracycline resistance (Truong-Bolduc et al., 2005). 
Overall, the presence or absence of resistance gene was not predictive of phenotypic resistance to 
doxycycline and minocycline in the study, isolates possessing the same genes with different 
MICs were identified. Further studies are therefore required for the explanation. 
Our attempts to attribute phenotype to other tetM factors including gene copy number failed to 
yield conclusive results. While there was no significant or apparent association with MIC and 
gene copy number, a non-significant but numerically apparent association was observed between 
tetM expression and MIC. The presence of tetM associated with resistance to tetracycline was 
observed in this study. However, tetM expression level was not significantly associated with 
MIC category for tetracycline and doxycycline. Although tetM expression level was not 
significantly associated with resistance, it was numerically higher in high MIC category isolates 
than low category isolates. The results suggest that expression may play a role although more 
studies are required to confirm this non-significant observation. A significant association 
between tetM expression and exposure to a different concentration of doxycycline was observed, 
and although a similar trend was seen for tetracycline these differences were not significant. 
Alternatively, it is possible that factors other than tetM are contributing to tetracycline and 
doxycycline MICs in the S. pseudintermedius studied.   
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Investigations of the relationship between gene expression and antimicrobial resistance 
phenotype are complicated and difficult to interpret in prokaryotes due to various reason 
including lack of reference genes, effects of antibiotics on other metabolic functions which may 
impact gene expression directly or indirectly. Moreover, normalization of reference genes is a 
well-known limitation in bacterial transcriptional studies (Dundas and Ling, 2012; McMillan and 
Pereg, 2014). Meaningful interpretation of target gene expression is limited by variability in 
reference gene expression (McMillan and Pereg, 2014). No single reference gene has been 
validated for gene expression studies in bacteria (Dundas and Ling, 2012). We therefore selected 
three reference genes which were originally optimized for biofilm studies (Crawford et al., 
2014). All three genes were initially included in this study, and one was selected post hoc for 
interpretation based on Normfinder and GeneKeeper. Furthermore, small sample size and the 
lack of reference genes for antimicrobial resistance gene expression studies were a limitation for 
the significant finding of this study. However, the study was not focused on translation, post-
transcriptional and translational modification, therefore further investigation must be required.  
 
5.6 Conclusion 
These results demonstrate that 116tetracycline is an inadequate indicator of resistance to other 
tetracyclines, we, therefore, recommend that diagnostic laboratories perform antimicrobial 
susceptibility testing for doxycycline and minocycline individually rather than solely relying on 
tetracycline as an indicator. Furthermore, phenotypic diversity in susceptibility to the 
tetracyclines cannot be solely explained by the presence or absence of resistance genes in the 
genome of S. pseudintermedius. The tetM gene is the common tetracycline resistance gene found 
in S. pseudintermedius. Although a significant difference in tetM expression was not found 
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between isolates with high and low tetracycline and doxycycline MICs, high-level resistant 
isolates did have numerically higher expression and additional, larger studies to confirm this 
observation are therefore recommended. Furthermore, proteomic studies would be helpful to 
clarify the presumptive differences in TetM in high and low MIC categories. The genotypic 
evidence on MICs for tetracycline and doxycycline is largely unknown and more studies are 
required.   
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6 DISCUSSION AND CONCLUSION  
The emergence of antimicrobial resistance in S. pseudintermedius was investigated in healthy 
dogs. Strain-specific infections and antimicrobial resistance was also examined in S. 
pseudintermedius from dermatological and urinary tract infections. Additionally, we investigated 
the incidence of S. pseudintermedius among human diagnostic submissions, and characterized 
these isolates using phenotypic and genotypic methods. Finally, we assessed the reliability of 
tetracycline as an indicator for resistance to doxycycline and minocycline, and the molecular and 
epigenetic mechanisms contributing to tetracycline resistance were explored.  
We found that Staphylococcus pseudintermedius colonized 80% of healthy dogs and that 
antimicrobial resistance increased since the last surveillance study conducted in 2008. Resistance 
to β-lactams and tetracycline was more common in 2014 compared to 2008, while the frequency 
of pan-susceptible isolates decreased. These results were consistent with the recent literature 
where high rates of tetracycline and β-lactam resistance were found in S. pseudintermedius 
(Gomez-Sanz et al., 2013a; Yoon et al., 2010). Moreover, MRSP was found in 7% of healthy 
dogs, which was higher than previously reported in North America and Europe (4.5%) (Weese 
and van Duijkeren, 2010). Multi-drug resistant isolates, both MSSP and MRSP, were also 
identified. However, resistance to other non-β-lactams including chloramphenicol, gentamicin, 
trimethoprim + sulfamethoxazole, erythromycin, and clindamycin remained low in the Saskatoon 
region. The results of this study highlight the importance of routine susceptibility testing when 
investigating bacterial infections involving S. pseudintermedius.  
Dermatological and urinary tract infections caused by S. pseudintermedius are common in dogs. 
In this study, strain specific tissue tropism was not observed for the skin or urinary tract, as is 
seen with uropathogenic E. coli. Despite this lack of mutually exclusive clustering, a 
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significantly higher frequency of resistance to erythromycin and chloramphenicol, and a 
difference approaching significance was observed in dermatological vs. urinary isolates. These 
results suggest that S. pseudintermedius infections are truly opportunistic. The identification and 
treatment of predisposing factors leading to disease is therefore critical to successfully treat these 
infections.  
Staphylococcus pseudintermedius is a rare zoonosis, with an incidence of 0.05% among skin and 
soft tissue infections in a people; compated to S. aureus which is isolated from 30% of these 
infections. Staphylococcus pseudintermedius may be misdiagnosed as S. aureus due to the lack 
of awareness of this veterinary pathogen in clinical diagnostic labs. Moreover, the ability to 
identify methicillin resistance in human diagnostic labs may be complicated by differences in the 
clinical breakpoints for oxacillin between these species (0.5µg/ml and 4µg/ml for S. 
pseudintermedius and S. aureus respectively) (CLSI, 2015). Importantly, no resistance to the last 
line drugs which used for Gram positive infection in humans was identified. 
The emergence of MRSP and β-lactam resistance among MSSP is threatening the future of the β-
lactams as effective anti-staphylococcal treatments. As a result, non-β-lactams including 
tetracycline have become important for treating S. pseudintermedius infections in dogs. 
Doxycycline and minocycline are prescribed for treating S. pseudintermedius infections in 
companion animals. Because our findings indicate that tetracycline is an inadequate indicator of 
resistance to these compounds, we recommend that laboratories include doxycycline and 
minocycline in routine test panels. While we did find at least one resistance gene in all resistant 
isolates, the relationship between the presence of a given resistance and MIC phenotype remains 
incompletely defined. In the case of tetM, isolates possessing this gene express a great deal of 
phenotypic diversity which is not easily explained by tetM copy number or expression. The 
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genotypic contribution of a tetM gene on the phenotypic outcome for tetracycline and 
doxycycline need to be further investigated.  
 
6.1 Limitations of the study 
6.1.1 Isolation and identification of the organism 
We collected two samples per animal and only three isolates were preserved for antimicrobial 
susceptibility testing. If at least one MRSP was identified from each dog it was recognized as 
colonized with MRSP. By increasing number of sampled sites per animal, the probability of 
MRSP detection would be increased leading to a truer representation of the frequency of MRSP 
colonization. In this investigation, animals colonized with MRSP on the skin would have been 
missed. 
  
6.1.2 Interpretation of antimicrobial susceptibility 
Veterinary clinical breakpoints have been published for a limited number of antimicrobials for S. 
pseudintermedius. In this investigation, some antimicrobial MICs were therefore interpreted 
using Staphylococcus genus-specific or S. aureus clinical breakpoints. Staphylococcus 
pseudintermedius specific breakpoints are available for minocycline, trimethoprim + 
sulfamethoxazole, chloramphenicol, erythromycin, gentamicin, daptomycin, linezolid, 
tigecycline, vancomycin or and quinupristin + dalfopristin (CLSI, 2017). Another limitation is 
that specific clinical breakpoints published for S. pseudintermedius are available for skin and soft 
tissue infections only. The clinical breakpoint may be different in human and dogs. As an 
example, in both chapter 2 and 3 tetracyclines was interpreted according to the human clinical 
breakpoint (≥16µg/ml). Later, the canine-specific clinical breakpoint (≥1µg/ml) were published 
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for S. pseudintermedius, applying these new breakpoints would change the calculated frequency 
of resistance (CLSI, 2013, 2014).  
 
6.1.3 Limitation in gene expression study 
Bacterial gene expression studies related to antimicrobial resistance are limited in the literature 
(Fiedler et al., 2016). The selection of a “reference gene” or “housekeeping gene” is challenging 
in prokaryotes, as many variables can alter the overall results of the study making interpretation 
difficult. In this experiment, we used three reference genes which were optimized in a previously 
publiched investigation targeting biofilm formation (Crawford et al., 2016). Multiple reference 
genes are used to provide confidence in the results, interestingly the fold changes calculated with 
each reference gene was not uniform in this study. Although three reference genes were 
previously published, the effect of tetracycline exposure on the expression of these genes is not 
known. It is possible that if tetracycline affects the expression of these genes, which would lead 
to an unaccounted-for contribution to gene expression.  
 
6.1.4 Lack of reference database to standardize tetracycline resistance gene nomenclature 
Although there are curated online databases for certain resistance genes such as β-lactamases 
(www.lahey.org), no database exists for tetracycline resistance genes. Therefore, the 
classification and nomenclature of tetracycline resistance genes are complicated and likely result 
in researchers not using a common ontology for these genes. Furthermore, the diversity in the 
sequences among these resistance genes results in a lack of consensus on whether two sequences 
are the same gene or should be considered different.  
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6.1.5 Small sample size 
The expression of tetM was investigated in eight S. pseudintermedius isolates. This small sample 
size required the use of nonparametric statistical tests (Mann-Whitney test). Unfortunately, 
nonparametric tests suffer from type I error and are more likely to fail to identify a significant 
difference. A larger sample size would improve the power of the statistical power of this study, 
allowing parametric methods to be applied.  
 
6.2 Future Directions 
Although S. pseudintermedius is a common cause of infection in dogs, the pathogenesis of this 
organism in the skin and urinary tract has not been investigated extensively. Many putative 
virulence genes in S. pseudintermedius were originally identified in S. aureus, and the role of 
these virulence factors in S. pseudintermedius has been under-investigated. Moreover, novel S. 
pseudintermedius specific virulence factors may be present which do not have a S. aureus 
homolog. The identification of virulence profiles which facilitate the pathogenesis of 
dermatological infections and urinary tract infections in dogs should be studied to improve our 
understanding of the mechanisms of disease.  
Although the PVL toxin has been detected in S. pseudintermedius, its role in pathogenesis has 
not been elucidated (Bardiau et al., 2013; Wettstein Rosenkranz et al., 2014). This is in contrast 
to S. aureus in people, where PVL is associated with community-acquired MRSA infections 
(Berla-Kerzhner et al., 2017).  
Furthermore, an understanding of the molecular mechanism leading to the transition from 
colonization to infection would be very useful for understanding the pathogenesis of S. 
pseudintermedius in companion animals. The activation of virulence gene expression and 
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strategies to evade the host immune system has not been studied in this organism. As we know, 
S. pseudintermedius is an opportunistic pathogen but it is unknown what organism factors 
contribute to the development of infections. 
Antimicrobial resistance is a priority area of research in veterinary medicine. Resistance 
surveillance is the only way to acquire information on emerging resistance in healthy and 
diseased populations of dogs. Monitoring the emergence of antimicrobial resistance in S. 
pseudintermedius and identifying risk factors for acquiring resistance need to be further studied. 
Understanding resistance emergence in healthy dogs will help us to control emerging S. 
pseudintermedius clinical infections in companion animals. In addition, estimation of the cost 
associated with resistant infections will help to justify prevention strategies which may increase 
the cost of treating of these infections in companion animals. The impact of plasmid-mediated 
dissemination of resistance is poorly understood in S. pseudintermedius although it has been 
observed in S. aureus (Fessler et al., 2017). Future antimicrobial resistance studies should focus 
on the role of mobile genetic elements in the epidemiology of resistance, rather than focusing on 
individual species. Although, the role of mobile genetic elements in the dissemination of 
resistance across species barriers is well recognized among Enterobacteriaceae, the frequency of 
transmission of resistance genese between Staphylococcus species is unkonwn (Berg et al., 
2017). 
Investigations into human infections with S. pseudintermedius should be a priority area of future 
research to enrich the understanding of interspecies transmission and the factors leading to 
human infections. The emergence of metabolic diseases and cancers in humans that lead to 
immunosuppression and secondary bacterial infections, including S. pseudintermedius, raises 
concern for increased risks of infection. This is particularly true due to patient contact with dogs 
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and the increasing popularity of canine-assisted therapy may increase the opportunities for 
interspecies transmission to occur. Therefore, a risk analysis must be carried out to understand 
how highly susceptible patients (such as those with immunodeficiencies) acquire infections with 
this potential opportunistic pathogen so that transmission can be prevented. 
The mechanism of resistance in S. pseudintermedius for a number of commonly used, old 
antimicrobials including the folate synthesis inhibitors is not adequately understood. 
Understanding the mechanism resistance is essential to develop strategies to limit the emergence 
of resistance to these drugs while still utilizing them for treating bacterial infections. Addressing 
this neglected field will become increasingly important as resistance continues to emerge and 
multi-drug resistant organisms become more common.  
We examined the effect tetM gene expression on tetracycline and doxycycline MIC. However, as 
this investigation only targeted expression at the level of transcription, any events occurring after 
this point (e.g. post-translational modification) are unaccounted for. Therefore, proteomic studies 
are required to understand the quantitative contribution of TetM to phenotypic resistance in this 
organism. Investigation of TetM expression by western blot would be helpful to understand the 
contribution of the TetM protein to tetracycline MIC. The effect of the primary, secondary and 
tertiary protein structure of TetM on phenotypic resistance has not been evaluated in 
Staphylococcus spp. The investigation into how changes in the variable region of TetM affect the 
MIC of an isolate to tetracycline is encouraged, we suggest that site-directed mutagenesis may be 
one possible approach for addressing this question. Finally, only two efflux mediated resistance 
mechanisms (TetK and TetL) affecting tetracycline in S. pseudintermedius have been identified. 
The role of other efflux pumps which may have tetracycline as a substrate needs to be 
investigated; the contribution of multi drug resistance efflux pumps, such as the small multidrug 
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resistance (SMR) family, multi drug and toxin extrusion (MATE), resistance nodulation division 
(RND) and ATP-binding cassette (ABC) on the tetracyclines has not been investigated 
(Schindler and Kaatz, 2016). There is evidence that these categories of efflux pumps can expel 
tetracyclines, although their contribution to resistance in S. pseudintermedius has not been 
evaluated. We anticipate that other efflux pumps may also affect intracellular tetracycline 
concentrations and that understanding the affinity of these efflux pumps for tetracyclines may 
explain some of the unaccounted for diversity in tetracycline susceptibility observed in this 
study.  
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